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ABSTRACT 
 
An emerging model of how stalled or damaged forks are processed is that replication 
forks can reverse to aid repair of the damage. The first evidence that replication forks 
regress in human cells came from a recent study with topoisomerase I (Top1) inhibitors, an 
important class of anticancer drugs currently in clinical use. Their cytotoxicity, and thus 
their efficacy, has been generally linked to their ability to cause the accumulation of DNA 
nicks, which are later converted into double-stranded breaks (DSBs) by the collision of the 
DNA replication fork with the primary lesion. The discovery that replication forks can 
regress upon Top1 inhibition provided new insight into the molecular basis of Top1 
cytotoxicity by showing that clinically relevant, nanomolar doses of Top1 poisons induce 
replication fork slowing and reversal in a process that can be uncoupled from DSB 
formation and requires poly(ADP-ribose) polymerase 1 (PARP1) activity. However, 
whether reversed forks can efficiently restart and which factors are involved in this 
mechanism was still unknown. In this thesis, using a combination of biochemical and 
cellular approaches, we provided the first evidence that regressed forks can restart in vivo 
and identified a key role for the human RECQ1 helicase in promoting efficient replication 
fork restart after Top1 inhibition that is not shared by other human RecQ members. Our 
data also provided the first insight into the molecular role of PARP1 in fork reversal by 
showing that the poly(ADP-ribosyl)ation activity of PARP inhibits RECQ1 activity on 
replication forks after Top1 inhibition. Thus, PARP activity is not required to form, but 
rather to "accumulate" reversed fork structures by maintaining/protecting them from a 
counteracting activity (RECQ1), which would otherwise cause an untimely restart of 
reversed forks, leading to DSB formation. The identification of a specific and controlled 
biochemical activity that drives the restart of reversed forks strongly supports the 
physiological relevance of this DNA transaction during replication stress in human cells. 
Moreover, our studies provide new mechanistic insights into the roles of RECQ1 and 
PARP1 in DNA replication and offer molecular perspectives to potentiate 
chemotherapeutic regimens based on Top1 inhibition. 
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1  INTRODUCTION 
	  
Genomic instability is one of the hallmarks of almost all human cancers 1. In contrast 
to normal tissues precancerous cells are characterized by accumulation of DNA lesions and 
activation of the DNA damage response (DDR), which induces senescence and apoptosis, 
thus representing an active barrier to tumorigenesis 2, 3. The major source of genomic 
instability associated with cancer development arises from oncogene-induced replication 
stress 4. Indeed cells are particularly vulnerable during DNA replication and several cellular 
factors are needed to ensure the correct duplication of the genome. However, hereditary or 
acquired mutations targeting DNA repair or checkpoint genes lead to aberrant DNA 
replication and genomic instability contributing to the tumorigenesis process. Cancer cells, 
in turn, become genetically “addicted” to these error-prone repair pathways to actively 
proliferate, contributing to their mutator phenotype 5, 6. Unraveling the mechanisms by 
which the cells cope with replication stress is critical not only to understand the basis of 
tumor development, but also to optimize and design novel therapies that target those 
specific repair pathways needed for cancer cell survival. 
 
1.1 DNA replication initiation 
The replication of genomic DNA is a well-conserved and tightly regulated process to 
ensure that the genome is replicated just once for every cell cycle 7. In higher eukaryotes 
replication initiates from multiple and generally clustered genomic regions termed origins 
of replication, unlike bacteria, which replicate their small genome from a single origin. The 
first step of the DNA replication is the formation of a pre-replicative complex (pre-RC) at 
each origin in G1 phase, through the binding of the origin recognition complex (ORC) to 
the chromatin, followed by the recruitment of additional replication factors, such as cell 
division control protein 6 (Cdc6), chromatin licensing and dna replication factor 1 (Cdt1) 
and the mini-chromosome maintenance (MCM) 2-7 helicase complex  8. There are several 
mechanisms that finely tune the “licensing” process in order to prevent re-replication: 
cyclin-dependent kinases (CDKs) activation inhibits the assembly of new origins and, most 
importantly, geminin binds to Cdt1 blocking MCM recruitment 9. During the G1/S 
Introduction 
	  
	   7 
transition state the pre-RC becomes phosphorylated by the cyclin E/CDK2 (cyclin-
dependent kinase 2) and DDK (Dbf4/Drf1-dependent S-phase-promoting kinase Cdc7), 
promoting loading of Cdc45 and the GINS complex, which are essential for origin firing 
and fork progression. The MCM2-7 and Cdc45 form the active replicative helicase 
required for DNA unwinding, while the GINS complex maintains their structural 
association (CMG complex). In addition, their assembly depends on additional factors 
well-defined in yeast, such as Sld2 and Sld3. These two factors interact with and activate 
Dpb11 upon CDK phosphorylation, which in turn seems to be required to facilitate Cdc45 
loading 10. The mammalian orthologs of Sld2 and Sld3 have not been identified as far. 
However, the RECQ4 helicase, MCM10, and Ctf4/AND-1 are needed for the CMG 
complex assembly in mammalian cells, as recently demonstrated using Bimolecular 
fluorescence complementation assay 11.  
The replisome is a multicomponent protein complex that contains different elongation 
proteins evolved to ensure the bidirectional semi-discontinuous DNA synthesis. The clamp 
loader replication factor C (RFC) helps the loading of the sliding clamp PCNA 
(proliferating cell nuclear antigen) that in turn tethers the DNA polymerases to the 
chromosome, enabling highly processive DNA replication. On the leading strand the DNA 
nucleotides are added continuously by the polymerase ε to the 3’ end of the RNA primer 
synthesized by the polymerase α-primase. On the lagging strand short DNA fragments 
called Okazaki fragments are built by the polymerase δ on the RNA primer, processed by 
the FEN1 and Dna2 nucleases, and ligated to the previous fragment by DNA ligase I.  
Unwinding of the duplex DNA induces positive and negative torsional stress both in 
front and behind the replication fork that cannot simply diffuse by the swiveling of the long 
chromosomes. Specialized nucleases called DNA Topoisomerases (Top) relieve the 
positive supercoils ahead and the precatenates that intertwine the two replicated duplexes 
behind the replication fork by introducing either single (Top1) or double-stranded breaks 
(Top2) into the backbone of the DNA 12 13. In a chromatin context histones are evicted 
ahead of the fork by the histone chaperone FACT and recycled on to the daughter strands 
by ASF1 and CAF1 ensuring a proper epigenetic transmission 14, 15.  
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by Dam methylase plays a critical role in preventing
re-replication [12,13]. Before replication, oriC is fully
methylated by Dam methylase, but immediately after
replication, because the nascent DNA strand is
unmethylated, the double-stranded origin is transiently
hemi-methylated before Dam methylase can methylate
the nascent DNA. The SeqA protein binds tightly to
this hemi-methylated DNA, preventing dnaA from
re-binding to its weaker binding sites, thus preventing
re-initiation of replication [13–15]. Although the
Dam/seqA system is clearly important in E. coli and
mutants lacking this system inappropriately re-initiate
replication, this system is entirely absent from other
bacterial groups such as the Gram-positive bacteria
including Bacillus subtilis. Again, as we will see below,
the apparently rapid evolution of re-replication control
is also a feature of eukaryotic replication.
In eukaryotes, the initiator protein is a multi-
subunit protein called the origin recognition complex
(ORC; figure 1) [16]. Five of the six ORC subunits
are members of the AAA! family (though only one,
Orc1, has retained a functional ATPase [27]) in a
clade of initiator proteins that includes dnaA [28].
Analogous to cooperation of dnaA with the AAA!
dnaC, ORC cooperates with another AAA! ATPase,
Cdc6, to load the replicative helicase, Mcm2-7, onto
origin DNA [29,30]. An additional factor, Cdt1,
which does not have an obvious bacterial analogue,
is also essential for helicase loading [31–33]. ATP
also plays a crucial role in ORC function; however,
this role is quite different from the role of ATP in
dnaA function. ATP binding (but not hydrolysis) is
required for budding yeast ORC to bind to its cognate












































Figure 1. Stepwise assembly of DNA replication complexes. The individual steps leading to the assembly of bidirectional repli-
somes is outlined. Names associated with each of the complexes are shown on the right: pre-RC, pre-replication complex; pre-IC,
pre-initiation complex; RPC, replisome progression complex. Cell cycle phases permissive for the individual steps are shown on
the left. For simplicity, some of the protein names have been abbreviated: 11, Dpb11; 3, Sld3; 7, Sld7; 2, Sld2; G, GINS;
45, Cdc45; 4, Ctf4. The shapes of many of the individual components are loosely based on three-dimensional reconstructions
from electron micrographs: ORC and Cdc6 are from Chen et al. [17], Mcm double hexamer is from Remus et al. [18],
Cdc45, Mcm2-7, GINS (CMG) are from Costa et al. [19], DNA polymerase epsilon (pol1) is from earlier studies [20,21],
and DNA polymerase a (pola) is from Klinge et al. [21]. The roles of CTF4 and Mcm10 in the RPC are inferred from earlier
studies [22,23]. Cyclin-dependent kinase (CDK) phosphorylations are shown in red, Dbf4-dependent kinase (DDK)
phosphorylations are shown in blue. The order of DDK and CDK in activating replication comes from earlier studies [24–26].
3546 J. F. X. Diffley Review. DNA replication control
Phil. Trans. R. Soc. B (2011)
 on February 15, 2013rstb.royalsocietypublishing.orgDownloaded from 
	  
Figure 1.1. Assembly f DNA replication complexes. The individual steps leading to the 
assembly of bidirectional replisomes in yeast is outlined. Names associated with each of the 
complexes are shown on the right: pre-RC, pre-re lica ion c mplex; pre-IC, pre-i itiation complex; 
RPC, replisome progression complex. Cell cycle phases permissive for the individual steps are 
shown on the left. For simplicity, som  of the protein names have been abbreviated: 11, Dpb11; 3, 
Sld3; 7, Sld7; 2, Sld2; G, GINS; 45, Cdc45; 4, Ctf4. Cyclin-dependent kinase (CDK) 
phosphorylation sites are shown in red, Dbf4-dependent kinase (DDK) phosphorylation sites are 
shown in blue. Adapted from J.F.X. Diffley, 2011 10. 
 
1.2 Replication stress 
Replication fork progression can be impaired by several obstacles, such as the 
presence of non-nucleosomal protein-DNA interactions, head-on collision with the 
transcription machinery, secondary structures that may arise in repeated A-T- or G-C- rich 
seque ces or spontaneous DNA damage. A halted replication fork is called “stalled” when 
is structurally able to resume progression, while is called “collapsed” when it becomes 
inactivated following the dissociation of the replication machinery 16. In bacteria a 
recombination-like process allows the origin-independent loading of the replication 
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machinery in order to resume DNA synthesis after replication collapse 17. In higher 
organisms a similar mechanism has not been identified yet; however, because of the 
presence of multiple origins, replication can be completed by an adjacent replication fork 
or by the firing of nearby “dormant” origins. Indeed, the MCM complex is loaded on 
chromatin in large excess relative to the effective fired replication forks, ensuring a 
reservoir of origin backup 18, 19. Moreover, cells accumulate DNA damage and chromosome 
instability in conditions of “limited licensing” due to MCM downregulation,  20.  Despite 
that, if both converging forks collapse or at regions of low density of origins such as fragile 
sites or telomeres, replication must restart in order to complete DNA synthesis. 
Upon transient fork stalling generated by replication inhibitors, such as hydroxyurea 
(HU) or aphidicolin, stabilization of replication forks by checkpoint signaling is crucial for 
maintaining the replisome in a replication-competent state and keeping DNA polymerases 
at the site of nucleotide incorporation 21.  The ATR branch is the main checkpoint pathway 
during the S-phase and its ablation is early embryonic lethal in the mouse 22. Stalled forks 
generated by helicase-polymerase uncoupling generally presents exposed ssDNA regions 
coated by the single-strand binding protein RPA (replication protein A), which in turn 
recruits the active ATR-ATRIP (ATR-interacting protein) complex 23. In spite of the 
numerous substrates, the main signal arising from the ATR cascade is the phosphorylation-
activation of Chk1, a serine-threonine kinase. Globally Chk1 activation leads to cell cycle 
arrest by phosphorylation-modulation of CDK regulators CDC25-A, CDC25-B, CDC25-C, 
and p53 activation. In addition, the ATR pathway promotes local fork stabilization through 
phosphorylation of several targets such as replication components, nucleases, and DNA 
helicases, which are required to maintain replisome integrity and prevent fork collapse 23, 24. 
In yeast, UV-irradiated or HU-treated checkpoint mutants accumulate aberrant replication 
structures such as long gaps and four-ways branched molecules resembling reversed forks 
25, 26. A set of not essential, but evolutionary conserved proteins named TIM, TIPIN, AND-
1, and Clapsin are important structural components of the replication machinery, by 
physically linking the helicase and the polymerase activities and preventing their 
uncoupling upon fork stalling. In addition, they provide a platform for DNA damage 
signaling and checkpoint activation, and ensure proper chromosome segregation by 
promoting sister chromatid cohesion 27. 
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1.3 Homologous recombination and DNA replication. 
Double strand-breaks (DSBs) are the major source of genomic instability and cell 
death. During DNA replication DSBs can arise from unscheduled nuclease processing of 
collapsed replication forks or from the replication run-off at nicks or gaps on the DNA 
template. While the Non-Homologous End-Joining (NHEJ) pathway processes and seals 
DSBs in non-proliferating cells during the G1 phase, Homologous Recombination (HR) is 
an highly accurate repair pathway that uses the intact sister chromatid as template to fix 
DSBs during the S and G2 phases 28. The central HR factors are RecA in bacteria and 
RAD51 in eukaryotes. They form a nucleofilament on 3’-single-stranded DNA ends and 
catalyzes homologous DNA search, strand invasion and pairing to form a displacement 
loop (D-loop), where the 3’-end of the invading strand primes DNA synthesis off the 
template duplex DNA. If the DSB is two-sided (frank), after branch migration of the D-
loop, the other end of the DSB is engaged by another invasion event or by DNA annealing. 
The resultant double Holliday junction is a substrate for dissolution into non-crossover 
products by BLM-Top3α or for resolution into crossover products by structure-specific 
endonucleases, such as Mus81-Eme1, Slx1-Slx4 and Gen endonuclease homologue 1 
(GEN-1) (Figure 2). Mitotic recombination in contrast to meiosis preferentially leads to 
non-crossover products; crossover events can be cytogenetically detected in metaphase as 
sister chromatid exchanges (SCEs). Alternatively, after partial DNA synthesis, the D-loop 
is dissolved and the displaced invading 3’-end reanneals with the second end of the DSB. 
This process, called synthesis-dependent strand annealing (SDSA) always leads to non-
crossover products, thus reducing the potential for genetic rearrangement 29 (Figure 2). 
ATP-dependent dissolution of D-loops by motor proteins is the key step in this HR sub-
pathway. Recently, FANCM, one of the 13 proteins linked to the rare human genetic 
disease Fanconi Anemia (FA) 30, as well as its yeast orthologs Mph1 (Saccharomyces 
cerevisiae) 31 and Fml1 (Schizosaccharomyces pombe) 32, were shown biochemically and 
genetically to dissolve D-loops. This dissolution activity channels HR repair (HRR) into 
the SDSA sub-pathway, thus preventing crossover formation and maintaining the genome 
stability. 
Replication fork collapse triggered by nick formation on the template DNA, especially on 
the leading strand, or generated by endonucleolytic processing of stalled forks, leads to the 
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formation of one-sided DSB, where, in the absence of a converging forks, the D-loop 
accumulated by the RAD51-mediated nucleofilament invasion cannot be processed by the 
two HR subpathways described above. Bacteria has an efficient system to reload the 
replisome on these D-loops, in an origin-independent manner, and resume DNA synthesis 
thanks to the action of specialized 3’-5’ helicases such as PriA 17. Although a PriA 
homolog is missing in eukaryotes, recent studies showed that Mre11 and RAD51 facilitate 
the reassembly of the CMG complex at broken replication forks in Xenopus laevis egg 
extract, suggesting the presence of a similar recombination-dependent (and origin-
independent) mechanism in vertebrates 33.  
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Pathways of double-strand break repair. Protein names refer to the budding yeast Saccharomyces cerevisiae (blue). Where different in
human, names (brown) are given in brackets. For proteins without a yeast homolog, brackets for human proteins are omitted. Broken
lines indicate new DNA synthesis and stretches of heteroduplex DNA that upon mismatch repair (MMR) can lead to gene conversion.
Abbreviations: BIR, break-induced replication; dHJ, double Holliday junction; NHEJ, non-homologous end joining; LOH, loss of











In presynapsis, the DNA damage is pro-
cessed to form an extended region of single-
stranded DNA (ssDNA), which is bound by the
ssDNA-binding protein RPA (replication pro-
tein A). For DNA double-strand breaks (DSBs)
in the budding yeast Saccharomyces cerevisiae,
this step involves a surprising complexity of four
nuclease [Mre11-Rad50-Xrs2 (MRX) (human
MRE11-RAD50-NBS1[MRN]), Exo1, Dna2,
Sae2 (human CtIP)] and a helicase activity
Sgs1 (human BLM; see sidebar) (104). Bind-
ing of RPA eliminates secondary structures
in ssDNA, which is needed for competent
Rad51 filaments to assemble. However, RPA
bound to ssDNA also forms a kinetic barrier
against Rad51 filament assembly, necessitating
so-called mediator proteins to allow timely
Rad51 filament formation on RPA-covered
ssDNA. Three different classes of mediators
have been described, but their mechanisms






































































Figure 1.2. Pathways of double-strand break repair. Protein names refer to the budding yeast 
Saccharomyces cerevisiae (blue). Where different in hu an, names (brown) are given in brackets. 
For proteins without a yeast hom log, brackets for human proteins are omitt . Broke  lines 
indicate new DNA synthesis and stretches of heteroduplex DNA that upon mismatch repair (MMR) 
can lead to gene conversion. Abbreviations: BIR, break-induced replication; dHJ, double Holliday 
junction; NHEJ, non-homolo ou  end joining; LOH, los  of heterozygos ty; S SA, synthesis-
dependent strand annealing; SSA, single-strand annealing. Adapted form W.D. Heyer, 2010 29. 
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This process resembles a particular HR sub-pathway called Break-induced replication 
(BIR), which has been extensively studied in yeast, where the invading strand generated at 
one-sided DSB is thought to establish a replication fork and to copy the entire distal arm of 
the template chromosome, resulting in loss of heterozygoty (LOH) (Figure 2 and Figure 
3h). In principle, this process might have a more relevant role in vertebrates than in lower 
eukaryotes due to the elevated presence of repetitive sequences that allow invasions on 
non-homologous template and fork restart. However, because of its non-conservative 
nature, the BIR process is characterized by several rounds of invasion and template 
switching, which trigger replication slippage and gross chromosomal rearrangements 
(GCR) 34, 35. Moreover, BIR-mediated DNA synthesis is highly inaccurate leading to a 
frameshift mutagenesis rate 2,800-fold higher than during normal replication, probably 
because of the lack of essential replicative factors 36. While this process is well defined in 
yeast, it has not been identified in mammalian cells to date.  
All the HR pathways described above are finely regulated by several mechanisms in order 
to ensure accurate recombination and prevent mutations, deletions and gene amplifications. 
The requirement of a 3’-ssDNA overhangs for RAD51 loading makes HR repair dependent 
on a first step of nucleolytic resection by the coordinated action of specific nucleases and 
helicases 37. First, DSBs are recognized and processed by the Mre11-Rad50-Nbs1 (MRN) 
complex, the tumor suppressor BRCA1 and CtBP-interacting protein (CtIP) 38. Their 
assembly is under the control of CDK activity, therefore restricted to S-phase and G2-phase 
39 and it is counteracted by the high affinity for double-strand ends of the Ku heterodimer 
that prevents resection and promote NHEJ during G1 40. Then extensive, long-range 
resection is taken over by the action of nucleases or nuclease-helicase complexes such as 
BLM and Dna2, or Exo1 41, 42, 43, 44. The resected 3’-end becomes coated by RPA that is 
subsequently replaced by RAD51 to form the presynaptic filament. Since RPA has a higher 
affinity for ssDNA than RAD51, cells have evolved mediator proteins such as Rad52 in 
yeasts and the tumor suppressor protein BRCA2 in vertebrates to overcome the RPA 
inhibitory barrier and promote RAD51 filament assembly 45, 46, 47. The central role of 
BRCA1 and BRCA2 in homologous recombination have been extensively studied and 
exploited for cancer therapy since mutations in these two genes confer genomic instability 
Introduction 
	  
	   13 
and predispose to a high risk for breast and ovarian cancer 48. In addition to these two 
proteins, other factors are critical for the positive regulation of the RAD51-ssDNA filament 
assembly. Indeed mutations in genes coding for the RAD51 paralogs (RAD51C, RAD51B, 
RAD51D, XRCC2, XRCC3), a group of proteins important for RAD51 filament 
stabilization, have been recently demonstrated to recapitulate the tumorigenic potential of 
BRCA dysfunction (“BRCAness”) 49, 50, 51.  
On the other hand excess of HR-dependence for survival leads to a hyper-recombination 
phenotype and chromosomal instability. Increasing evidences suggest that HR is an 
inaccurate process, particularly due to the complex architecture of the vertebrate genome. 
Lee et al. demonstrated that a microhomology-based, nonallelic homologous 
recombination (NAHR) mechanism between low-copy number repeats or repetitive 
elements located at different replication forks, brought nearby by chromatin looping, is 
responsible for the complex nonrecurrent rearrangements of PLP1 (proteolipid protein 1) 
gene, observed in the dysmyelinating disorder Pelizaeus-Merzbacher disease (PMD)  52. 
Moreover, when the homologous sequences are in inverted-repeat orientation, NAHR-
mediated replication restart results in dicentric chromosome intermediates, which, on 
segregation, lead to breakage and further chromosome rearrangements 53, 54. Following 
these findings, a growing number of genetic disorders have been associated with GCRs 
arising from inaccurate recombination events at stalled replication forks in the last years  55, 
56. For this reasons, HR is a tightly regulated process and non-recombinogenic mechanisms 
are generally favored to restart stalled replication forks. In addition, organisms have also 
evolved a set of motor proteins with the specialized function of limiting HR by removing 
RAD51 from ssDNA, such as Srs2 in yeast and RTEL1 (regulator of telomere elongation 
helicase 1), FBH1 (F-Box helicase 1), PARI (PCNA-associated recombination inhibitor), 
and RecQ helicases in mammals 57, whose depletion leads to unscheduled recombination 
and genomic instability.  
Recent studies suggested that HR proteins play a complex role at replication forks that goes 
beyond their repair and restart activity. Indeed, the loss of crucial homologous 
recombination and/or Fanconi anemia (FA) factors, such as RAD51, BRCA2, and 
FANCD2, leads to Mre11-dependent degradation of nascent strands at stalled replication 
fork and accumulation of ssDNA gaps 58, 59. These studies uncovered a DSB-independent 
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role of RAD51 nucleofilament formation in protecting stalled replication forks from 
unscheduled nucleolytic resection. Interestingly, this function does not seem to help 
directly cells in resuming replication, but partially explains the chromosomal abnormalities 
and the cancer-prone phenotype associated with BRCA and FANC dysfunction 60, 61. 
Besides DSBs, replication fork can be halted by bulky lesions arising from exogenous 
DNA damage, such as UV irradiation and alkylating agents, or from endogenous processes, 
such as oxidative stress, spontaneous depurination, and ribonucleotide incorporation. These 
template lesions, particularly if posed at the leading strand, impede further nucleotide 
incorporation by replicative DNA polymerases but usually they do not represent an 
obstacle for helicase unwinding 62 (Figure 3b). Given the inherent plasticity of the 
replication processes, DNA synthesis can proceed discontinuously on both strands in the 
presence of DNA damage, without replisome dissociation from the fork. For example the 
leading-strand polymerase can use a primer synthetized by the primase in Escherichia coli  
63, 64, or even the mRNA transcript during in-line collision with the transcriptional 
machinery 65, to re-initiate DNA synthesis downstream a template lesion (Figure 3c). The 
resulting ssDNA gaps behind the fork are substrates for the RAD51 strand invasion and 
error-free, post-replicative recombination-mediated gap filling. This process uses the 
daughter strand posed on the sister duplex to copy the damaged template and it is thought 
to require the formation of a sister chromatid junction (SCJ) (Figure 3f and 3f’) or a double 
Holliday junction (dHJ) (Figure 3e and 3e’) which are subsequently resolved by the action 
of BLM and Top3. This notion is supported by the observation that the depletion of Sgs1, 
the yeast homolog of BLM, leads to the toxic accumulation of X-shape recombination 
intermediates upon methyl methanesulfonate (MMS) treatment, in a RAD51-dependent 
manner 66. In addition, cells can use an alternative mechanism driven by a group of low-
fidelity, non-replicative polymerases, called Translesion Synthesis (TLS) polymerases, 
which are able to copy lesions-containing DNA because they have a larger active site than 
replicative polymerases that is able to accommodate damaged or distorted templates. 
However, because of their lower ability to discriminate the correct base and their lack of 
3’-5’ exonuclease proofreading activity, these polymerases copy the template in an error-
prone manner, increasing the risk of mutagenesis (Figure 3d) 67. The main event 
orchestrating the choice between these two pathways is the differential addition of 
Introduction 
	  
	   15 
ubiquitin- and SUMO-related moieties on the replication sliding clamp PCNA 68. In 
general, PCNA K164-monoubiquitination by Rad6/Rad18 recruits TLS polymerases 
through their ubiquitin binding motifs and promotes the error-prone repair pathway, 
whereas Ubc13-Mm2 and Rad5 dependent PCNA polyubiquitination drives the error-free 
repair by a mechanism that is still poorly understood 69. Moreover in yeast SUMOylation of 
PCNA keeps certain potentially deleterious HR pathways in check by recruiting the 






















Figure 1.3. Possible pathways resolving leading strand blockage. (a) and  (b) Leading strand 
lesions stalls polymerases but not the replicative helicase. Translesion synthesis (TLS) polymerases 
can lead to an error-prone lesion bypass (d, dashed green line). (c) Otherwise DNA synthesis is 
reinitiated downstream the lesion, resulting in a leading strand gap, which can be repaired later by 
HR in an error-free mechanism involving the formation of a sister chromatid junction (SCJ) (f and 
f’) or a double Holliday junction (dHJ) (e and e’). (g) Stalled replication forks can be cleaved by an 
endonuclease to generate a one-sided DSB. One-sided DSB repair by recombination proceeds in 
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1.4 Fork remodeling and reversal 
Template lesions that stall the polymerase activity were suggested more than 30 years 
to cause replication fork reversal, where the nascent strands reanneal to form a four-way 
junction resembling a Holliday junction, called “chicken foot” (Figure 4a). In this way, the 
damaged strand is relocated into a region of duplex DNA, so that it can be repaired using 
the information contained in the homologous template (Figure 4b). An alternative 
possibility is that the lesion is simply by-passed using the nascent undamaged strand as an 
alternative template (Figure 4c). Otherwise, in the presence of lesions that impede 
replicative helicase unwinding, fork regression might represent a mean to provide the 
repair machinery the necessary space and time to fix the damage (Figure 4d). Finally, the 
reversal of the “chicken foot” structure restores a competent replication fork, likely able to 
resume DNA synthesis 71.  
The first indication that replication forks can reverse was experimentally obtained from a 
study performed in 1976, where the authors demonstrated the formation of an heavy/heavy 
DNA upon bromodeoxyuridine pulse-labeling of human cells treated with DNA damaging 
agents 72. Following this study, four-armed structures were shown to form in vitro in 
partially replicated plasmid DNA using electron microscopy (EM)  73. Following these 
observations, the fork regression model has been extensively used to indirectly explain 
some replication or recombination mutant phenotypes, especially in the bacteria system 74, 
75. However, the formation of reversed forks in vivo has been clearly demonstrated only by 
the recent development and optimization of techniques such as neutral-neutral 2-D gel 
electrophoresis and, most importantly, EM on cross-linked DNA extracted from cells. First, 
Lopes et al. demonstrated through 2-D gel electrophoresis the formation of X-shaped 
replication structures in checkpoint-deficient S. cerevisiae cells upon HU treatment 76. 
Successively, these observations were implemented by EM analysis that allowed the direct 
visualization of the replication intermediates. Checkpoint-deficient yeast cells treated with 
HU show two kinds of aberrant structures: the most abundant is long ssDNA stretches (up 
to 800 nt), arising from extensive helicase-polymerase uncoupling or nucleolytic 
processing on nascent DNA. The second class of intermediates is regressed forks, where 
the regressed arm is partially or completely single-stranded. Since these structures persist 
also after HU removal and correlate with fork collapse and cell death, the authors 
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concluded the fork regression is a “pathological” event in eukaryotic cells, rather 









Figure 1.4. Fork regression followed by reversal. (a) A lesion in the leading strand template 
could result in the formation of a blocked fork with a gap on the leading strand. (b) and (c) Fork 
regression would reposition the 3′ end of the blocked leading strand so that it would be paired with 
the nascent lagging strand, whilst the DNA lesion would be relocated back into the reformed 
parental duplex. Bypass of the lesion could be effected by extension of the leading strand using the 
lagging strand as a template followed by reversal of fork regression. Repositioning of the lesion 
back into the parental duplex could also facilitate repair rather than bypass. Extension of the leading 
strand using the nascent lagging strand and reversal of regression would reconstitute a fork 
structure on to which the replication apparatus could be reloaded. (d) In the presence of double-
strand blockages that impede further DNA unwinding replication fork reversal provides time and 
space for the repair machinery to fix the lesion. Once lesion gets repaired a functional replication 
fork is restored. Adapted from Atkinson J., 2009 71. 
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Which factors drive directly fork regression is not clear yet. The formation of a four-
way junction is not thermodynamically unfavorable because all the removed base pairs 
reanneal in the regressed arm. However, the physical presence of the replisome on the 
stalled forks could represent an energetic obstacle because it must dissociate in order to 
allow fork reversal. In addition, if leading and lagging strands synthesis is uncoupled by 
template lesions leading to ssDNA formation, an initial stretch of dsDNA would need to be 
denaturated before daughter strand annealing, thus creating a kinetic barrier to fork 
regression. For this reasons, it is likely that fork reversal is a specific enzyme-mediated 
process and indeed, an increasing number of enzymes that catalyze this transaction in vitro 
have been identified during the past 10 years. Historically the first protein shown to convert 
replication forks into Holliday junction structures was the bacterial DNA helicase RecG 77. 
Interestingly, structural analysis of RecG bound to a forked DNA provided evidence that 
the helicase domains form a dsDNA traslocation motor that pulls the daughter strands into 
two grooves that can only accommodate ssDNA and are separated by a so-called “wedge” 
domain 78. This particular structural feature allows the ATP-dependent unwinding and 
subsequent annealing of the nascent leading and lagging strands, which are extruded in 
close proximity. Other ATP-dependent DNA helicases that have been demonstrated to 
catalyze fork regression in vitro are the members of the RecQ family, whose biochemical 
features and biological functions are described in Section 1.7.  
Recently an increasing number of ATP-dependent dsDNA translocases, members of the 
SWI/SNF2 family, was shown to remodel stalled replication forks in four-ways junctions 
despite lacking a canonical strand separation activity. Among these proteins, the S. 
cerevisiae Rad5 and its human orthologs HLTF (helics-like transcription factor), and 
SHPRH (SNF2 histone linker PHD RING helicase) are the most characterized in terms of 
biochemical and biological function 79, 80. Rad5/HTLF can process in vitro model 
replication forks with homologous arms by generating chicken foot structures 79, 81. Rad5, 
HTLF and SHPRH contain a RING finger domain that confers E3 ubiquitin ligase activity 
and they form a multiprotein complex with yeast and human Rad6-Rad18. Their depletion 
leads to gross chromosomal rearrangements, DNA damage sensitivity, elevated 
mutagenesis and impaired fork progression on UV or MMS damaged DNA template 82, 83, 
84, 85. Moreover, recent studies in yeast have shown that Rad5, along with the 
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recombinogenic factors RAD51, Rad52, Rad54, and Rad55, are required to accumulate 
four-way junctions, detectable by 2D-gel electrophoresis on DNA damaged replication 
intermediates 86. These observations lead to the idea that Rad5/HTLF might functionally 
link the fork regression process with a well-conserved and defined repair pathway such as 
the template switching mechanism of DNA damage tolerance, under the strict control of 
PCNA ubiquitination signal. Moreover, these findings suggest an intimate connection 
between fork regression and recombination. 
Rad54 is another SNF2 translocase able to migrate branched DNA structures 87, an activity 
that is essential during homologous recombination repair, after the RAD51-catalyzed 
strand invasion and D-loop formation 88. Interestingly, Rad54 is able to overcome longer 
regions of heterology on branched substrates than the BLM helicase 89. Rad54 promotes 
both fork regression and restoration in vitro and this equilibrium is shifted towards the first 
process in the presence of RAD51; this effect is specific for Rad54 as RAD51 does not 
influence the respective activity of BLM 90. 
FANCM, an SNF2 component of the Fanconi Anemia (FA) complex, and its yeast 
orthologs Mph1 (S. cerevisiae) and Fml1 (S. pombe), was also shown to branch migrate 
four-ways junctions in vitro and catalyze the regression of a model of replication fork 30, 32, 
91, 92. Given that FA cells are especially sensitive to interstrand cross-linking agents, it has 
been proposed that the fork regression activity of FANCM is important for counteracting 
the movement of a replisome towards an interstrand cross-link, thus maintaining access of 
repair proteins to the lesion 93. 
Finally HARP, also known as SMARCAL1, which is associated with Human Schimke 
Immune-osseous Dysplasia (SIOD), is a SNF2 family protein that possess ATP-dependent 
DNA rewinding activity 94. This unique biochemical feature allows HARP to translocate 
backward the split-end fork and anneal the complementary DNA coated by RPA, thus 
limiting the amount of ssDNA formed at stalled fork 95, 96. Moreover, HARP is 
characterized by ATP-dependent branch migration and fork regression activities in vitro, 
although the biological significance of these two activities is still unknown 97.  
In addition to helicases and translocases, strand exchange proteins such as the bacterial 
RecA 98, the bacteriophage UvsX 99 and the eukaryotic RAD51 100 has been shown to 
promote fork regression in vitro, even if at slower rate than motor proteins. Due to their 
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intrinsic nature that require ssDNA to allow initial binding and nucleation, they might be 
required to regress stalled fork with extensive ssDNA gaps at the junction 101. On the other 
hand, helicases or translocases might act on stalled replication forks that have limited 
ssDNA. Genetic studies performed in E. coli have pointed to the importance of 
recombination proteins in promoting reversal and restart of stalled replication forks 75, 102, 
103, 104. However, it is more likely that they stabilize and protect the extruded arm of 
regressed forks, particularly when a ssDNA tail is present, from improper cellular 
processing, thus promoting their accumulation rather than directly catalyze this process. 
In spite of the increasing number of protein candidates potentially able to regress arrested 
replication forks, we cannot rule out the possibility that this reaction can occur without the 
assistance of any protein. Analysis of in vitro partially replicated plasmid DNA treated with 
intercalating agents to generate overwound DNA has been used to show that replication 
fork reversal represents a spontaneous process aimed at dissipating the positive torsional 
stress accumulating ahead the advancing replisome 105. This phenomenon has physiological 
relevance upon head-on collision between replication and transcription units 106 or, more 
generally, when replication forks are moving across chromatin domains susceptible of 
topological stress such as termination zones, highly transcribed regions such as rDNA, or 
anchored to fixed structures, such as the nuclear envelope and chromosome scaffolds 107. 
Recently Bermejo et al. clearly demonstrated that accumulation of reversed forks in a 
checkpoint-defective yeast strain arises as a consequence of torsional stress generated 
ahead the replication forks encountering transcribed genes, gated at the nuclear envelope. 
In addition, the same authors demonstrated that fork reversal arises spontaneously in cells 
lacking Top1 and Top2 as well, underlying again the topological influence in driving 
spontaneously this transaction 108. 
Finally, the negative supercoils accumulating behind replication forks have been suggested 
to trigger the formation of hemicatenate structures between sister chromatids which 
contribute to the establishment of sister chromatid cohesion during S-phase and assist 
recombination or replication bypass processes. Reversed forks can also derive from the 
run-off of these sister chromatid junctions (SCJs) at inactivated replication forks 109, 110.  
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1.5 Top1 inhibitors and replication fork reversal 
In contrast to bulky lesions, double strand-related damages, such as interstrand cross-
links or tightly DNA-bound nucleoprotein complexes, such as the transcriptional 
machinery, create a roadblock for the advancing replisome, without helicase and 
polymerase uncoupling. In this case, replication can only resume after block removal. 
Interstrand cross-link (ICL) repair, for example, is carried out by the combination of 
Nucleotide Exicision Repair (NER), TLS and HR pathways coordinated by the complex 
activities of the Fanconi Anemia (FA) proteins 93.  
Replication can slow and stall if there are unresolved topological constrains ahead of the 
replisome generated by transcription bubbles, termination zones, another fork approaching 
or inhibition of topoisomerase activity. Top1 and Top2 inhibitors rely on the transient 
trapping of these specialized nucleases on their 3’-single-strand and 5’-double-strand DNA 
substrate, respectively, thus preventing the religation step 111. Because of the high 
proliferation of cancer cells, drugs that target Top1 such as camptothecin, or Top2 such as 
etoposide, are potential chemoterapheutics and some of them have been already clinically 
approved for cancer treatment 112, 113. In particular, the S-phase dependent cytotoxicity of 
Top1 inhibitors was thought to arise from replication run-off at Top1-DNA frozen 
complexes located on the leading strand, triggering to the accumulation of lethal one-side 
DSBs 114. This model was recently challenged by the work of Koster et al. where using a 
combination of single-molecule and in vivo experiments, the authors demonstrated that 
Top1 inhibitors hinder the uncoiling activity of Top1, thus promoting positive supercoiling 
formation and replication fork slowing. They also proposed that the resulting accumulation 
of positive supercoils ahead of the replication machinery is the major mechanism of fork 
collapse and cell death upon camptothecin exposure 115, 116.  
Recently, the group of Massimo Lopes in Zurich has extended this observation by 
demonstrating that clinical relevant doses of Top1 inhibitors are associated with replication 
fork slowing, without DSBs formation. By exploiting a combination of in vivo psoralen 
cross-linking and EM analysis to directly visualize replication intermediates, they were 
able to detect a high frequency of regressed forks upon Top1 poisoning in yeast, Xenopus 
laevis egg extract, and mammalian cells. In contrast to previous findings, they found that 
the replication fork slowing and reversal associated with Top1 inhibitors are not 
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checkpoint- or recombination-dependent. Moreover, they discovered that poly(ADP-
ribose) polymerases 1 (PARP1) activity, at least in X. laevis egg extract and mammalian 
cells, is essential to slow the replication forks on CPT-damaged templates by promoting the 
accumulation of regressed forks. PARP1 depletion or inhibition revert this effect of Top1 
poisoning, leading to the formation of DSBs likely by replication run-off at Top1-DNA 
covalent complexes (Top1cc) (Figure 5) 117. PARP1 plays a critical role in mediating the 
cellular sensitivity to camptothecin derivatives and several clinical trials are currently 
investigating the potential advantages of combined therapies with PARP and Top1 
inhibitors 118, 119. 
 
 
Figure 1.5. Model for replication interference by Top1 poisons and their synergistic effects 
with PARP inhibitors. Upon Top1 inhibition, replication forks rapidly experience slowed 
progression and reversal, mediated by PARP activity in higher eukaryotes (and unknown factors in 
yeast) and promoting Top1 covalent complex (Top1cc) repair and replication completion. PARP 
inactivation leads to increased DSBs, owing to unrestrained fork runoff at Top1cc. High CPT doses 
lead to incomplete replication and persistent fork stalling, causing DSBs by eventual fork collapse 
and/or processing; PAR, poly(ADP-ribose) Adapted from Ray Chaudhuri A., 2012 117. 
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The results of Dr. Lopes’ group provide a new rationale for the synergic effect of these 
inhibitors on actively proliferating cancer cells. They also point to fork reversal as a 
general strategy that allows the repair enzymes to fix the lesion before the replication 
resumes, thus avoiding replication fork collision with single, and possibly, double strand 
breaks. Nevertheless, this work opens several relevant biological questions: 1) since 
PARP1 is just a signaling molecule without motor activity, which are the factors involved 
in PARP-mediated fork reversal? 2) Is this PARP-mediated mechanism of fork reversal 
taking place also when replication is challenged with other replication inhibitors? 
 
1.6 Replication fork restoration and restart after reversal 
After regressing, replication forks must be properly restarted to complete DNA 
synthesis. Regressed forks might represent a highly recombinogenic substrate and, if not 
restarted in a timely fashion, their accumulation might lead to unscheduled HR with 
subsequent chromosomal rearrangements and genomic instability 26.  
The simplest and probably safest mechanism of reversed fork restoration is to migrate back 
the branch point of the four-way junction through an enzymatic-mediated reaction (Figure 
6a). Notably, most of the in vitro tested proteins able to perform fork reversal, have also the 
ability to reset the original forks, probably due to an indiscriminate branch migration 
activity. However, none of these enzymes has been shown to selectively perform fork 
restart in vivo.  
Alternatively, the extruded arm can be degraded by nucleases or helicase/nuclease 
complexes to reset a proper replication fork (Figure 6b). For example, the combined 
activity of the E.coli RecQ helicase and the RecJ nuclease has been shown to degrade 
regressed forks formed in a RecA-dependent manner in UV-treated bacteria 103. In addition, 
the E. coli helicase/nuclease complex RecBCD has been shown to resolve reversed forks 
formed in some replication mutants in a non-recombinogenic way by degrading both 
strands at the blunted dsDNA end of the extruded arm 74, 120. Whilst no RecBCD homologs 
have been identified in eukaryotic cells, Exo1 activity is able to counteract fork reversal in 
checkpoint-deficient S. cerevisiae mutants treated with HU 110. However, it is not clear 
whether Exo1 is acting directly on a four-way junction, or simply prevents its formation by 
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resecting newly synthesized DNA chains or resolving the sister chromatid junction that 
could promote fork reversal at collapsed forks.  










= RAD51 nucleofilament  
	  
Figure 1.6. Mechanisms for replication fork restoration after reversal. (a) Fork restoration by 
forward migration of the junction by helicases/translocases. (b) Fork restoration by nuclease-
mediated degradation of the extruded arm. (c) Regressed fork cleavage by structure-selective 
endonucleases and fork restoration by recombination. (d) Fork restoration by recombination of the 
extruded arm with the preformed parental strands ahead the junction. The resulting D-loop structure 
containing a double Holliday junction (dHJ) can be resolved by endonucleases (d’) or dissolved by 
the BLM-Top3α complex (d’’). 
 
Recent EM analysis of replication intermediates from fission yeast showed that Dna2, an 
enzyme with both nuclease and helicase activity, normally implicated in Okazaki fragments 
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processing, is able to prevent HU- or MMS-stalled forks from reversing in a checkpoint-
dependent manner 121.  In the same study, the authors showed that Dna2 is able to digest the 
extruded arm of model regressed forks in vitro. However, an alternative scenario is that 
checkpoint-mediated phosphorylation tethers Dna2 on stalled fork to cleave nascent 3’ or 
5’ flap DNA at the junction, thus preventing their further unwinding and fourth arm 
formation. Due to the redundancy of resection machineries in cells, the processes of 
regressed fork resolution by nucleases is quite attractive, even if it precludes the use of the 
lagging strand for template switching.   
Regressed forks can also be resolved in a recombination-dependent manner in at least two 
ways. First, four-arms DNA structures are preferred substrates for some structure-selective 
endonucleases, such as the RuvABC complex in E.coli or Mus81-Eme1 in vertebrates, both 
of which are normally involved in dHJ resolution during the last step of the HR repair. The 
cleavage of the junction would generate a nicked duplex and a second duplex carrying a 
dsDNA end. The dsDNA end can in turn be processed to generate a 3’-tail, which will then 
be loaded by strand exchange proteins and invade the intact sister duplex to promote D-
loop formation and HR (Figure 6c). Alternatively, upon 5’-degradation and RAD51 single-
strand coating, the regressed arm might serve as invading strand in the homologous 
sequence of the reformed parental duplex, resulting in dHJ formation and HR (Figure 6d). 
The latter mechanism is theoretically less harmful because of the physical linkage between 
the recombining end and the donor target sequence, preventing recombination between 
non-identical sequences. However, since recombination is a potential threat for genome 
stability, cells might limit HR to a last attempt to resolve these structures in absence of 
non-recombinogenic mechanisms. In agreement with this conclusion, the E.coli Holliday 
junction resolvase RuvC cleaves regressed forks only in recBC mutants, and the 
chromosome breakage is repaired by HR 102, 120.  
The particular structure of the stalled forks could dictate the mechanism of fork 
restoration. For example, a replication fork stalled by leading strand lesions or by 
replication inhibitors, such as HU or aphidicolin, likely presents a single-strand gap at the 
junction, as discussed above, and the resulting fork reversal generates a chicken foot 
structure with a partial single-stranded extruded arm. In the cellular environment, partially 
or fully single-strand arms are rapidly coated by single-strand binding proteins, which in 
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turn lead to the ATR-mediated checkpoint activation and/or homologous recombination. 
However, the 5’-tail of regressed forks arising from leading strand damage might not allow 
a direct restart by HR.  
In contrast, in the presence of agents that block the helicase movement, such as interstrand 
cross-linking drugs, topoisomerase inhibitors or head-on collision with the replication 
machinery, the resulting regressed fork is likely to arbor a blunt-ended extruded arm. This 
blunt-ended arm might activate the ATM-checkpoint and would need to be processed by 
the resection machinery to generate a proper 3’-tail for HRR. Beside these speculations, the 
exact signaling pathways and cellular factors that regulate the restoration mechanism are 
still unknown and further studies are necessary to shed light on how reversed fork are 
restarted. 
 
1.7 RecQ helicases 
The RecQ DNA helicases are a subgroup of the SF2 superfamily of helicases, 
conserved from bacteria to humans, which play an essential role in maintaining genomic 
stability by acting at the interface between DNA replication, recombination and repair. 
Unicellular organisms contain one representative of the family, such as E. coli RecQ and S. 
cerevisiae Sgs1, while high eukaryotes generally express multiple RecQ enzymes (Figure 
7). Mammalian cells arbor five RecQ homologs, and mutations in three of these genes 
(BLM, WRN and RECQ4) are associated with the Bloom, Werner and Rothmund-Thomson 
syndromes, respectively. Although no disease has been linked to mutations in the RECQ5 
(alias RECQL5) and RECQ1 (alias RECQL1 or RECQL) genes as yet, a single nucleotide 
polymorphism in RECQ1 correlates with decreased survival of pancreatic cancer patients, 
and RECQ5-/- knockout mice display increased cancer rates 122.  
All RecQ helicases have an ATP-dependent DNA helicase activity with 3’-5’ polarity and, 
although with some differences, are able to resolve a variety of DNA structures other than 
standard B-form DNA duplexes.  
As bona fide helicases, all the RecQs contain a common helicase domain formed by two 2 
RecA-like domains, which functions as ATP driven motor for their 3’-5’ translocation 
activity on ssDNA 123. While the overall fold of the helicase domain is similar to that of 
other SF2 helicases, the major distinguishing feature of RecQ proteins is the region termed 
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RecQ-C-terminal (RQC), that is present in most RecQ helicases with the exception of 
RecQ4 and its orthologs (Figure 7) 124. The RQC domain is composed of a zinc-binding 
module and a helix-turn-helix fold, the so-called winged-helix (WH) domain. The zinc-
binding subdomain is required for protein stability as single-amino acid substitutions in the 
zinc domain of human BLM and E.coli RecQ are either insoluble or prone to degradation 
125, 126. 
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The failure to repair DNA damage can lead
to genomic instability. Repair of double-strand
breaks (DSBs) requires many proteins with
enzymatic activities, such as nucleases, heli-
cases, ligases, DNA topoisomerases, etc. One
important family of enzymes is DNA heli-
cases, and these enzymes function by unwind-
ing complementary strands of DNA. The RecQ
DNA helicases, conserved from bacteria to hu-
mans (Figure 1), are critical to ensure proper
repair of DNA damage. Bacteria and bud-
ding yeast have one RecQ homolog, RecQ
and Sgs1, respectively. In humans, there are
five RecQ homologs, and mutations in three
of these genes (BLM, WRN, RTS/RECQ4)




















Structural features of RecQ helicases. The RecQ proteins have several structural domains that are conserved from bacteria through
humans. All RecQ proteins have a core helicase domain. Most RecQ proteins also contain conserved helicase and RNAse D C-terminal
(HRDC) and RecQ C-terminal (RQC) domains that are thought to mediate interactions with nucleic acid and other proteins,
respectively. Many RecQ proteins have acidic regions that enable protein-protein interactions, and some of the RecQ proteins have
nuclear localization sequences. WRN and FFA-1 protein are unique in that they also contain an exonuclease domain. Sgs1 and Blm are
the first characterized members of this family of proteins containing a functional strand exchange domain in their N-terminus. The
number of amino acids in each protein is indicated on the right.
Rothmund-Thomson syndromes, respectively,
which cause cancer predisposition and/or pre-
mature aging (44, 79, 121, 131, 169).
Unwinding of double-stranded DNA
(dsDNA) is necessary in many different
processing steps. One of the challenges in
studying the function of the RecQ helicases is
that mutation of the RECQ genes leads to a
pleiotropic phenotype, exhibiting traits that in-
clude increased chromosomal rearrangements,
increased sister-chromatid exchanges (SCEs),
and premature aging. The RecQ helicases
function in both early and late recombina-
tion steps, where they promote homologous
recombination (HR) and prevent crossover
events. This review focuses on the recent
findings that the RecQ proteins function at
multiple DNA processing steps and how these

































































Figure 1.7. Structural features of RecQ helicases. The RecQ proteins have several structural 
domains that are conserved from bacteria through humans. All RecQ proteins have a core helicase 
domain. Most RecQ proteins also contain conserved helicase and RNAse D C-terminal (HRDC) 
and RecQ C-terminal ( QC) domains that are thought to mediate interactions with nucleic acid and 
ot er proteins. Many RecQ proteins have acidic re ions that enable protei -pr tein i teractions, and 
s me of the R cQ protein  have nuclear localization sequences. WRN and FFA-1 protein are 
unique in that they also contain an exonuclease domain. Sgs1 and Blm are the first characterized 
members of this family of proteins containing a functional strand exchange domain in their N-
terminus. The number of amino acids in each protein is indicated on the right. Adapted from 
Bernstein KA., 2010 124. 
 
The WH domain, despite low sequence identity, shows a structurally conserved fold among 
the RecQ members and it is important for DNA binding as previously demonstrated for 
other proteins such as the transcription factors CAP and hRFX1 or the human DNA repair 
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protein AGT 127. An interesting feature of this domain is the presence of a beta-hairpin loop 
carrying an aromatic residue at the tip  128. Mutagenesis studies demonstrated that the 
simple substitution of Tyr to Ala at the tip of the beta wing is sufficient to abrogate the 
helicase activity of RECQ1 129. Moreover, the recent crystallographic structure of the RQC 
domain of WRN bound to a dsDNA clearly shows that the beta-hairpin acts as a separation 
pin coupling the ATP-driven tracking along ssDNA tail to DNA unwinding. Interestingly, 
the fact that other DNA helicases such as the bacterial UvrD or the archeal Hel308 harbor a 
similar beta wing structure suggests a common inchworm mechanism of unwinding. 
However, the beta wing of these proteins is spatially located in close proximity to the 
ATPase domains, whereas the RecQ beta-hairpin is mobile and confers a structural 
separation between the translocation and the separation module. This particular feature 
resembles the wedge domain of the bacterial RecG and makes these proteins capable to 
melt non-canonical DNA molecules such as Holliday junctions, by accommodating this 
flexible loop at the branch point, without steric hindrance 130. Surprisingly, given its small 
size and critical role in mediating DNA contacts, the RQC domain is also crucial in 
mediating interactions with other proteins, as already demonstrated for WRN 131. 
In addition to this conserved RQC domain, some RecQ helicases have an auxiliary domain 
named the helicase-and-RnaseD-like-C-terminal (HRDC). Among the human RecQs, only 
BLM and WRN possess an HRDC domain. Structural and biochemical studies indicate that 
HRDC domain forms a surface for additional DNA binding. In addition, the poor sequence 
and structural conservation makes this domain important to confer distinct substrate 
specificities to the individual RecQ members 132. For example, the HRDC domain of BLM 
is important for Holliday junction binding and resolution, although it has a minor effect on 
DNA duplex unwinding 133. 
The human WRN and its orthologs also harbor a 3’-5’ exonuclease domain at their N-
terminus which highly resembles the structure of DnaQ exonucleases such as the 3’-5’ 
proofreading domain of E.coli DNA polymerase I 134. 
In addition, all the RecQ helicases have non-conserved N- or C-terminal regions that play 
regulatory duties, e.g. nuclear localization 127.  
Notably, almost all RecQ helicases form high-order oligomers. Using a combination of size 
exclusion chromatography and transmission electron microscopy, our group demonstrated 
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that the different oligomeric states of RECQ1 result in two opposite enzymatic activities: a 
higher-order oligomeric form is associated with strand annealing, while a smaller form 
consistent with monomers or dimers is responsible to DNA unwinding. Importantly, the 
equilibrium between these two forms is controlled by ATP binding, which promotes 
oligomer dissociation 135. Recently, a coiled-coil motif responsible for oligomerization has 
been identified in the N-terminus of RECQ1 and WRN 136. Interestingly, this region was 
previously reported to be important for the Holliday junction resolution activity of RECQ1 
137, but not for fork unwinding, while it is required for the optimal exonuclease activity of 
WRN 138, probably by promoting the assembly of a hexameric ring structure where the 
active site of the enzyme is located in a central cavity of the appropriate size to 
accommodate a dsDNA. This suggests that higher-order oligomer assembly is critical for 
the different functions of RecQ helicases.  
1.7.1 BLM 
Bloom’s syndrome (BS) is an extremely rare genetic disorder, characterized by a high 
risk to the development of a broad range of cancers, in contrast to almost all other 
genetically inherited cancer predispositions which are usually associated with a small 
subset of tumors 138. Cells from BS patients exhibit chromosome instability with increased 
numbers of chromatid gaps and breaks and chromosome rearrangements. The most 
remarkable feature, that is used in the molecular diagnosis of BS, is an approximately 
tenfold increase in the frequency of sister chromatid exchanges (SCEs) and an high rate of 
loss of heterozygosity (LOH), which is one of the mechanisms that can lead to complete 
loss-of-function of tumor-suppressor genes in cancer, thus explaining the high cancer 
susceptibility of Bloom patients 139, 140. 
BLM and its orthologs have the unique ability among the RecQ family members to 
“dissolve” dHJ into non-crossover products during the last step of the HRR, hence 
suppressing SCE formation 141. This dissolution activity is performed by an evolutionary 
conserved complex formed by BLM, Top3α, RMI1 (BLAP75) and RMI2 (BLAP18), 
where BLM branch migrates and collapses dHJs into a hemicatenate, Top3α removes the 
remaining linked single strands by its strand pass activity, and RMI1 and RMI2 play a 
stimulatory role 142, 143, 144. This “dissolvasome” complex has recently been shown to ensure 
faithful chromosome segregation by dissolution of secondary DNA structures named ultra-
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fine bridges (UFBs) in anaphase cells. These UFBs arise as the result of tangled regions, 
such as centromeres, or from difficult-to-replicate regions, such as fragile sites or 
telomeres, particularly following replication stress; the BLM complex re-localizes to these 
structures during anaphase and catalyzes their resolution 145. 
Human BLM and its yeast orthologs are also involved in DNA end resection to generated 
3’ ssDNA tails and promote HR 41, 42, 43, 146, 147. In vivo and in vitro analysis have shown that 
after a DSB occurs, the DNA ends are recognized and partially resected by MRN complex 
(MRX in yeast) in collaboration with CtIP endonuclease (Sae2 in yeast), leaving a short 3’ 
single-stranded DNA tails. Successively, these DNA ends undergo a long-range resection 
(up to 2-4 kb) mediated by BLM (Sgs1 in yeast) and its interacting partners RPA and 
Dna2, or via a parallel pathway relying on the Exo1 nuclease. In particular, BLM and RPA 
are needed to unwind the DSB ends and provide access for Dna2 that processes the 
resulting ssDNA with its 5’-3’ nuclease activity. Interestingly, this process is stimulated by 
RMI1-Top3α and other RecQ helicases cannot substitute BLM 44. A possible reason for 
explaining why cells have evolved two different and very conserved pathways is that 
extensive ssDNA formation is crucial to activate the DNA damage checkpoint and to 
ensure high-fidelity HR by preventing repair between short dispersed repeats.  
As most RecQ helicase-deficient cells, BLM depleted cells are characterized by defects in 
replication fork progression and are sensitive to replication inhibitors or replicative damage 
148. In particular, upon HU or aphidicolin treatment, BLM is phosphorylated by ATR at 
T99, and is required for efficient fork restarting and for suppression of dormant origin 
firing 149. Moreover BLM deficiency is associated with a strong cytidine deaminase defect, 
leading to pyrimidine pool imbalance; nucleotide pool normalization leads to a reduction of 
sister chromatid exchange frequency and it is sufficient to fully restore replication fork 
velocity, but not the fork restart defects 150.  
In the context of HRR, BLM is also able to disrupt RAD51-ssDNA nucleofilaments and D-
loops in vitro adding further complexity to its anti- and pro-recombination activities 151. 
BLM is also able to act on a large number of non-canonical DNA substrates, which might 
form upon replication stress such as D-loops, G-tetraduplexes, RNA-DNA hybrids and 
four-way junctions 137. In addition, BLM was shown to promote both fork regression and 
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fork restoration in vitro, but the biological function of this activity is still unknown 152, 153, 
154. 
1.7.2 WRN 
Werner’s syndrome (WS) differs from the other human RecQ helicase syndromes 
because of its strong premature ageing features, with death occurring at the average age of 
50, mainly due to the insurgence of cancers or vascular diseases. Fibroblasts isolated from 
WS patients have reduced proliferative lifespan, chromosomal translocations and deletions; 
however, unlike BS cells, WS fibroblasts do not show an increased frequency of SCEs 155. 
The pleiotropic nature of WRN and the multiplicity of its interacting partners complicate 
the assignment of a prominent biological function for this protein. Nevertheless, the 
particular ageing phenotype of WRN patients and a large number of experimental 
evidences suggest a crucial involvement of WRN in telomere maintenance 156, 157. For 
example, the forced expression of exogenous telomerase in WS fibroblasts rescues the 
premature senescent phenotype of these cells and the WRN mutant mouse only 
recapitulates Werner syndrome when combined with telomerase mutant alleles 158. 
Replication problems might occur at an increased frequency in telomeric regions; because 
of the intrinsic inability of the lagging strand DNA replication machinery to function at the 
very end of chromosomes, a specialized reverse transcriptase called telomerase adds a G-
rich repeat sequence to the telomeric ends. WRN is required for telomere lagging strand 
synthesis 159 and associates with the G-rich region to unwind the G-quadruplexes 156, 160. In 
addition, WRN resolves D-loops HR intermediates and telomeric T-loops in vitro to allow 
replication of the telomeric ends and suppress inappropriate recombination, in a manner 
regulated by the interacting telomeric proteins TRF1 and TRF2 161.  
Even if WS cells have prolonged S-phase, the involvement of WRN in DNA replication 
seems to be confined to difficult-to-replicate regions such as telomeres, but also fragile 
sites or rDNA, particularly upon replicative stress 162. WRN depletion confers sensitivity to 
replication inhibitors and other fork stalling agents, and is associated with S-phase defects 
in cells with hyperactive c-Myc 163. Unlike BLM, WRN depletion does not influence the 
ability of stalled forks to restart or the activation of dormant origins. However, WRN seems 
to be important for DNA replication fork progression on HU- and MMS-damaged 
templates, as demonstrated by DNA fiber assay 164. One possible explanation for this role 
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of WRN in DNA replication relies on its interaction with the replicative polymerase Polδ, 
where the WRN exonucleolytic processing of 3’-terminal mismatches helps the 
proofreading polymerase to synthesize DNA with high fidelity upon replicative stress, 
hence preventing the accumulation of deleterious mutations 165. Alternatively, WRN could 
be required to resolve non-B-form DNA structures that would otherwise block the 
polymerase processivity. In addition, WRN was shown to be required for Okazaki 
fragments maturation in cooperation with its interacting partner FEN1, by directly 
stimulating the nucleolytic activity of FEN1 on long flaps generated at blocked forks, or 
indirectly, by resolving hairpins or stem-loops formed at repetitive sequences 166. In 
addition to Okazaki fragment processing, recent studies in human cells and Xenopus laevis 
egg extract have showed that WRN is involved with Dna2, Exo1 and RPA in the 5’ 
resection at DSBs to promote 3' single-strand tail formation and homology-dependent 
repair 167, 168. As mentioned above, BLM has also an important role in this process and it is 
not clear yet if these two RecQ helicases works in a redundant or complementary fashion to 
stimulate 5’ resection. However, WRN’s role in HR is not as well defined as in the case of 
BLM. WRN cells do not display increased SCE, but have a clear hyper-recombinogenic 
phenotype, particularly after DNA damage induction 169. Moreover, WRN colocalizes with 
RPA upon replication inhibition and suppresses the RAD51 foci formation, probably by 
resolving recombinogenic structures. Finally, WRN depletion makes the repair of 
replicative DNA damage dependent on the Mus81-induced DSB and on the consequent HR 
pathway 170, 171.  
Several lines of evidence point to an additional role of WRN in the DNA damage tolerance 
pathway. WRN binds Ubs9 and is sumoylated in mouse and human cells. WRN interacts 
with WRNIP1, a polyubiquitin-binding protein, that is considered a homolog of the yeast 
DNA damage tolerance protein Mgs1 172. In DT40 cells, WRN assist REV1-dependent 
translesion synthesis at UV-damaged templates 173. Moreover, WRN stimulates the 
processivity of several TLS polymerases in vitro 174. However, WRN might also have a 
suppressive effect on TLS, which could explain the increase of mutation rates and the 
constitutive ubiquitination of PCNA in WRN cells. In this context, Kobayashi et al. 
showed that WRN is recruited to replicative foci by NBS1 where it interacts with PCNA 
and represses its ubiquitination. Upon DNA damage, ATM/NBS1-dependent 
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phosphorylation of WRN triggers its degradation, making PCNA free to be modified by 
RAD18 and to channel the repair towards the DNA damage tolerance pathway 175. 
WRN was also shown to have a role upstream and downstream of the checkpoint response. 
For example, WRN acts upstream of ATM and ATR to facilitate RPA foci formation and 
Chk1 activation upon HU exposure in Caenorhabditis elegans 176. In addition, activation of 
ATM and its downstream checkpoint targets is impaired in WRN deficient human cells 
exposed to interstrand cross-link agent PUVA (psoralen plus UVA) 177. More importantly, 
Patro et al. have recently shown that WRN is required for the S-phase checkpoint 
activation to prevent CPT-induced fork collapse in human cells. In particular, WRN 
facilitates ssDNA formation at CPT-stalled replication forks to induce a global checkpoint 
activation that reduces the overall fork speed and prevents further fork collision with Top1-
DNA complexes 178. Furthermore, Ammazalorso et al. suggested that ATR and ATM 
differentially regulate WRN in response to HU treatment in human cells. WRN is recruited 
to stalled replication forks through its interaction with Rad1, a subunit of the 9.1.1 
complex, and phosphorylated by ATR to prevent DSB accumulation. Conversely, upon 
prolonged HU treatment and replication fork collapse, the other checkpoint kinase, ATM, 
phosphorylates WRN on different residues to promote its delocalization from DSB sites 
and to direct the repair towards the RAD51-mediated HR pathway 179, 180. 
Biochemical studies showed that WRN has the ability to perform both the reversal and 
restoration of a regressed fork in vitro 153, 154, 181. In particular, the fork regression activity 
of WRN is enhanced by the presence of leading strand gaps at the junction and its 3’-5’ 
exonuclease activity might be needed to create an optimal substrate for this activity 182. If 
the anti-recombinogenic function of WRN at stalled replication forks relies on its 
replication fork regression/restoration activity is still an open question. 
Besides its role replication and in S-phase-related genome maintenance, WRN was 
suggested to be involved in multiple DNA repair pathways, as evicted by its interaction 
with a number of repair proteins 131. For example, WRN interacts with the NHEJ core 
components the Ku heterodimer 183, DNA-dependent protein kinase catalytic subunit 
(DNA-PKcs) 184 and the XRCC4-DNA Ligase IV complex 185. However, WRN is not an 
essential NHEJ factor, and it might be required only for “dirty” end processing or when 
NHEJ acts on sub-genomic regions, such as telomeres and rDNA.  
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In addition, the involvement of WRN in Base Excision Repair (BER) is supported by its 
functional interactions with Polβ, Apurinic/apyrimidinic endonuclease I (APE1), NEIL1 
and the sensitivity of WRN to oxidative stress and methylating agents 186, 187. In this 
context, WRN physically interacts with PARP1 that is also involved in BER, and WS cells 
are deficient in poly(ADP-ribosyl)ation activity after exposure to hydrogen peroxide and 
MMS 188. In addition, unmodified PARP1 inhibits WRN helicase and exonuclease activity. 
However, activation and auto-poly(ADP-ribosyl)ation of PARP1 by DNA strand breaks 
relieves the inhibition of WRN catalytic activities, suggesting that there is a coordination 
between PARP1 and WRN during repair events 189. Although PARP1 and WRN are not 
essential components of BER, their presence may ensure correct and efficient DNA repair. 
In their absence, improper and/or inefficient repair may lead to various pathologies 
associated with aging. In agreement with this conclusion, PARP1−/−/WRNΔhel/Δhel mice have 
an increased frequency of cancer, and fibroblasts derived from these knockout mice display 
elevated levels of chromosomal breaks, fragments, and rearrangements 190. Incomplete 
BER intermediates that cannot be properly repaired by the BER pathway might be shuttled 
to the homologous recombination pathway during replication 191. Thus, the hyper-
recombination phenotype of WS cells may also reflect the products of  unrepaired SSBs 
during DNA replication. 
1.7.3 RECQ5 
In contrast to the other human RecQ homologues RECQ5 exists in three isoforms 
RECQ5α, RECQ5β and RECQ5γ resulting from alternative splicing. All of them contain 
the core helicase motifs characteristic of RecQ helicases. However, only the largest splice 
variants RECQ5β is nuclear, thanks to the presence of a nuclear localization signal on its 
C-terminal sequence and possesses helicase activity 192. Hereafter 
RECQ5β will be reffered to as RECQ5. Primary mouse embryonic fibroblasts (MEF) 
derived from RECQ5 knockout mice show an elevated rate of spontaneous DSBs, 
hypersensitivity to DNA-damaging agents and a significant increase in the frequency of 
SCEs comparable to that caused by BLM gene inactivation. However, RECQ5 and BLM 
double depletion in mouse embryonic stem (ES) cell line leads to an even higher frequency 
of SCEs compared to the single mutants, indicating that these two proteins operate non-
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redundantly in suppressing mitotic recombination 193, 194. The first clue for the anti-
recombinogenic role of RECQ5 comes from its ability to physically interact with RAD51, 
and to disrupt the RAD51 presynaptic nucleofilaments in a reaction dependent on its 
helicase activity 194, 195. Furthermore, the group of Dr. Weidong Wang has recently 
identified a region on the RECQ5 C-terminus that is similar to the BRC repeats of BRCA2 
and is essential for the interaction with RAD51 196. Mutations in this region recapitulate the 
recombinogenic phenotype of RECQ5 depleted cells. Interestingly, also the yeast Srs2 
protein contains a similar functional region, suggesting that RECQ5 might be the 
functional homolog of Srs2 in human cells. 
RECQ5 is the only RecQ member able to directly interact with RNA polymerase II 
(RNAPII). RNAPII is the major protein complex associated with RECQ5 in vivo, when 
purified from human chromatin under physiological conditions. RECQ5 is able to associate 
with both the hypo- and hyper-phosphorylated forms of RNAPII and this interaction is 
mediated by the RPB1 subunit of RNAPII and the C-terminal domain of RECQ5 197. In 
vitro transcription assays and small interfering RNA (siRNA) experiments have shown that 
the RECQ5-RNAPII interaction domain, named KIK domain, but not the helicase activity 
of RECQ5, inhibits transcriptional initiation and elongation 198. Strikingly, the RECQ5 
BRC repeat is needed for both its anti-recombination and transcription activities, which are 
dependent on the helicase and KIK domain, respectively, opening an interesting scenario 
where RECQ5 might prevent unscheduled homologous recombination arising from 
transcriptional perturbation of the DNA replication process. 
1.7.4 RECQ4 
Mutations in RECQ4 are associated with three unrelated disorders: Rothmund-
Thompson syndrome (RTS), RAPADILINO syndrome and Baller-Gerolds syndrome (BGS). 
All of them are characterized by growth retardation and radial ray defects. However, only 
RTS patients are predisposed to develop bone and skin cancers and show some premature 
aging symptoms similar to Werner syndrome patients 138. In the several attempts that were 
made to generate mice that recapitulate these RECQ4-dependent syndromes it was 
discovered that deletion of the N-terminal region of RECQ4 results in embryonic lethality. 
Sequence analysis unmasked a limited homology of the N-terminus of RECQ4 with the 
yeast essential replication initiation factor Sld2 199, 200. Following these observations, 
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RECQ4 was shown to be an essential factor for replication initiation and origin firing in 
Xenopus laevis egg extract and mammalian systems 201, 202. Moreover, immunoprecipitation 
experiments from native chromatin extracts of HEK 293T cells have been employed to 
demonstrate that RECQ4 is part of the replicative complex comprising MCM2-7, CDC45 
and GINS. It specifically binds the origin of replication at the end of G1 phase in a 
MCM10-dependent manner and it is required for the efficient recruitment of the GINS 
complex prior to DNA replication initiation 203. Even if it lacks the characteristic RQC 
domain, RECQ4 has a weak helicase activity in addition to a strong strand annealing 
activity 204. However, the exact role of RECQ4 in replication initiation is still not well 
defined and whether RECQ4 is the true homolog of Sld2 in human cells is still an open 
question. One intriguing possibility is that RECQ4 in cooperation with MCM10 mediates 
the conformational transaction from the pre-replicative dsDNA-bound status of the MCM 
complex to the helicase processive ssDNA-encircling form of MCM during replication 
initiation 205. 
In addition to its role in replication, RECQ4 is involved in several DNA-repair related 
processes including double-strand break repair (DSB), Nucleotide Excision Repair (NER) 
and Base Excision Repair (BER) 206. In addition, RECQ4 interacts with and is poly(ADP-
ribosyl)ated by PARP1, although the meaning of this interaction in a DNA repair context 
remains uncertain 207. 
Finally, RECQ4 seems to be involved in all the three major mechanisms associated with 
aging and cellular senescence: oxidative stress, telomere maintenance and mitochondrial 
dysfunction. First, RTS cells are hypersensitive to oxidative damage, suggesting a 
modulation of the BER pathway 208. Second, RECQ4 interacts with the telomeric 
components TRF1 and TRF2, and acts synergistically with WRN, but not BLM, in 
resolving telomeric D-loop 209. Third, RECQ4 is the only RecQ helicase that localizes in 
mitochondria where it promotes p53 accumulation in unstressed condition; deletion of the 
mitochondria localization signal from RECQ4 N-terminus leads to mitochondrial 
bioenergetics defects and elevated mitochondrial DNA (mtDNA) damage 210, 211. 
1.7.5 RECQ1 
RECQ1 was the first RecQ helicase member to be identified in human cells, as the 
human homologue of the E.coli RecQ helicase. The cDNA cloning and FISH analysis 
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localized the RECQ1 gene on the short arm of human chromosome 12 at 12p12 212. It 
encodes a 649 amino acid polypeptide with a predicted molecular weight of 73 kDa. The 
protein shares a high sequence similarity with E.coli RecQ and other human RecQ 
helicases. The expression of RECQ1 is significantly high in testes and in actively 
proliferating cells, transformed cells and tumors 213, 214.  
At the cellular level, RECQ1 is found both in the cytoplasm and the nucleus, and it is 
ubiquitously expressed throughout the cell-cycle. Though there is no human syndrome 
linked to RECQ1 deficiency, mutations in the RECQ1 gene are associated with testicular 
germ cell tumors 215 and recent studies have linked a single nucleotide polymorphism 
present in the RECQ1 gene to a reduced survival in pancreatic cancer patients 216. 
A RECQ1 knockout mouse was created by replacing the exons of helicase domain IV and 
V with Neo resistance cassette. The homozygote mice did not show any particular 
developmental abnormalities and were viable and fertile, but prone to develop tumors, with 
lymphoma being the most common one 217. 
Cytogenetic analysis of the embryonic fibroblasts (MEF) derived from RECQ1 knockout 
mice revealed aneuploidy, suggesting a role of RECQ1 during segregation of chromosomes 
during mitosis. M-FISH analysis revealed increase in fragmented chromosomes, chromatid 
breaks, translocation events, and SCEs. These cells accumulate DNA damages, evident by 
the increase in γH2AX and RAD51 foci formation. In addition, RECQ1 deficient cells are 
hypersensitive to ionizing radiation 217. 
Interestingly, acute depletion of RECQ1 in several tumor cell lines resulted in reduced cell 
proliferation and spontaneous DNA damage 214, 218. Since RECQ1 is present in high copy 
number in cancer cells it might be considered as a suitable target for cancer therapy. Indeed 
Futami et al. showed that RECQ1 silencing induces mitotic catastrophe in cancer cells, 
probably by accumulating DNA replicative damage 219; moreover, local and systemic 
administration of RECQ1-siRNA mixed with cationic liposomes prevented cancer cell 
proliferation in a mouse model of cancer without detectable side effects 220, 221. 
Even though RECQ1 was the first RecQ helicase to be historically discovered in human 
cells, it remains one of the least characterized in terms of enzymatic activity and biological 
function. The increased load of DNA damage and the elevated SCEs in RECQ1-deficient 
cells suggest that RECQ1 is involved in maintaining chromosomal stability and that might 
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play an anti-recombinative role by suppressing the formation of recombination 
intermediates that arise during replicative stress. This notion is also supported by the 
observation that RECQ1 promotes the dissolution of unproductive D-loop formed by a 5' 
single-stranded DNA invading strand in vitro 222. In addition, RECQ1 has been identified as 
the major HJ branch migrating protein in chromatographic fractionated nuclear extracts 
from HEK 293T cells 223. Genetic analysis using the chicken DT40 system demonstrated 
that the double mutant RECQ1/BLM cells were more sensitive to mitomycin C-induced 
SCEs compared to single mutant BLM cells, indicating that RECQ1 may have some non-
redundant functions with the BLM helicase at the sites of DNA damage during replication 
fork progression 224.  
The involvement of RECQ1 in replication is supported by several recent studies. Wang et 
al. employed a DNA affinity purification and mass spectrometry procedure to show that 
RECQ1 physically associates with the replicative lytic origin (ori-Lyt) of Kaposi’s 
sarcoma-associated herpesvirus (KSHV) through the viral proteins K8 and RTA. Based on 
these observations, the authors speculated that RECQ1 is not only an integral component of 
the pre-replication complex, but also the so long-sought helicase that unwinds origin DNA 
in the initiation of KSHV lytic DNA replication 225. Later, it was found that RECQ1 is also 
associated with the ori-Lyt and Zta of the Epstein–Barr virus (EBV) 226.  
Chromatin immunoprecipitation (ChIP) analyses performed in our group showed that 
RECQ1 physically associates with replication origins in a cell-cycle-regulated fashion in 
unperturbed cells. In addition, genome-wide DNA fiber experiments were used to show 
that RECQ1 is required for efficient replication initiation and might play an additional role 
during replication elongation  202. However, the exact role of RECQ1 in DNA replication 
remains to be determined.  
A new intriguing role for RECQ1 is emerging for studies performed in Neurospora crassa 
where mutations in the gene encoding the RECQ1-like helicase QDE3, an RNA-dependent 
RNA polymerase (QDE1), or an Argonaute protein containing a PIWI domain (QDE2), 
result in a quelling defect in qiRNA (QDE1-interacting RNAs) mediated post-
transcriptional gene silencing (PTGS) 227. Consistent with the Neurospora genetic results, 
RECQ1 was found in a piRNA (PIWI-interacting RNAs) complex isolated from rat testis 
228.  A number of studies suggested that piRNAs are epigenetic and translational regulators 
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that have the primary function of maintaining germline DNA stability, genome 
organization, trasposon silencing, germline determination and meiosis 229. Moreover, 
overexpression of PIWI genes is highly correlated with cancers in humans  230 . All these 
data suggest a new function for RECQ1 in the generation of small RNA molecules 
involved in genome silencing and stabilization. 
 
1.8 Poly(ADP-ribose) polymerase 1 
Poly(ADP-ribose) polymerases (PARPs) are a heterogeneous group of ADP-ribosyl-
transferase enzymes which transfer ADP-ribose groups from donor NAD molecules onto 
their target proteins post-traslationally. PARP1 is the most abundant and the best-
characterized member of this family and plays a crucial role in regulating multiple cellular 
functions and DNA-related transactions such as apoptosis, transcription, chromatin 
remodeling and DNA repair 231. PARP1 arbors a N-terminal DNA binding domain 
containing three zinc-finger motifs by which it senses alterations in the DNA secondary 
structure, such as single and double-strand breaks, cruciform structures and nucleosome 
linker DNA 232. As revealed by a recent crystallographic report, DNA binding leads to a 
conformational change in PARP1 that activates its catalytic transfer of negatively charged 
ADP-ribose moieties from NAD+ to acceptor proteins such as histones and p53 233. 
However, the most prominent poly(ADP-ribosyl)ated substrate of PARP1 is PARP1 itself, 
resulting in its dissociation from DNA due to electrostatic repulsion between the negatively 
charge poly(ADP-ribose) (PAR) and DNA 234. The nature of this modification is transient 
and extremely short-lived because of the catabolic activity of poly(ADP-ribose) 
glycohydrolase (PARG) which cleaves the polymers within a matter of minutes and 
recycles PARP1 for subsequent steps of DNA binding/activation. The importance of a 
strict PAR regulation is underlined by the embryonic lethality of PARG-null mice 235. 
Besides being a post-traslational modification, poly(ADP-ribose) (PAR) chains, which 
resemble the chemistry (negative charge) and the conformation (elicoidal) of nucleic acids, 
represent also a strong, non-covalent binding module for several proteins, regulating their 
enzymatic activity and cellular localization. Several years ago, Pleschke et al. identified a 
PAR binding consensus sequence built by basic residue clusters interspersed with 
hydrophobic amino acid and conserved in a broad range of proteins involved in DNA-
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related cellular functions 236. Moreover, in the last years three different domains have been 
identified as structurally specific PAR-binding modules, such as the PAR binding zinc-
finger (PBZ) domain 237, 238, the macrodomain 239, 240, 241, 242, and recently the WWE domain 
243. Its temporal and structural flexibility makes the poly(ADP-ribosyl)ation axis an ideal 
signal mechanism for coordinating cellular pathways under stress, which require an 
immediate regulation. This is well-established during the DNA damage response, where 
PARP1 quickly senses the DNA breaks triggering the rapid poly(ADP-ribosyl)ation 
(PARylation) of itself or chromatin-associated proteins surrounding the lesion. Poly(ADP-
ribosyl)ated chromatin acts as an interaction scaffold for the differential recruitment of a 
multitude of DNA repair complexes or chromatin modifying proteins 244. The best 
characterized in this context is the Single-Strand Break Repair (SSBR) pathway where 
PARylation recruits the scaffold protein XRCC1, DNA ligase III and, depending on the 
complexity of the lesion, other proteins such as polynucleotide kinase (PNK) and DNA 
polymerase β 245.  
As a consequence of poly(ADP-ribosyl)ation, the chromatin structure becomes more 
relaxed, thereby increasing lesion accessibility and repair efficiency. Recently, two PAR 
binding proteins, the chromatin remodeler ALC1 240 and the histone chaperone APLF 246, 
have been shown to actively participate in the PARP1-mediated chromatin dynamics 
during DNA repair.  
PARP1 binds and is activated by DSBs. Moreover, PARP1 directly interacts with and 
poly(ADP-ribosyl)ates some of NHEJ core components such as the Ku heterodimer, 
decreasing its DNA affinity 247, and DNA-PKcs, regulating its kinase activity 248, 249. NHEJ 
preferentially works during G1, where sister chromatid are not available for HRR, and, 
even if it represents the major DSBR pathway in mammalian cells, it is largely error-prone 
leading to traslocations and genomic rearrangement. Besides canonical NHEJ (c-NHEJ), 
PARP1 is the central factor regulating an alternative NHEJ pathway (a-NHEJ), where, in 
the absence of Ku, PARP1 recruits the MRN complex and XRCC1/DNA ligase III for 
microhomology-mediated end-joining 250, 251, 252. The importance of this backup NHEJ 
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The involvement of PARP1 in HRR is uncertain and still under debate. While PARP1 has 
not an effect in HRR measured by a I-SceI reporter assay 255, its depletion impairs the 
Mre11-dependent resection at HU-stalled replication forks and consequently RAD51 
nucleofilament formation and HRR 256. The same authors reported that PARP1 activity is 
actually important in protecting HU stalled forks from Mre11-mediated degradation, 
attributing the discrepancy with the previous result to the length of HU treatment that was 
much shorter in this second case compared to the previous study 257. Indeed, long HU 
exposure in human cells progressively generates DSBs, which are repaired by HR. The 
collapsed replication forks generated by long HU exposures are unable to resume, and 
DNA synthesis needs to be completed by the firing of new origins. On the other hand, short 
HU treatments transiently stalls replication forks, which are then reactivated by a non-
recombinogenic RAD51-mediated mechanism after drug removal 258.  
Genetic studies showed PARP1 is an important factor in protecting the HR pathway from 
the toxic NHEJ engagement during S-phase DSB repair, probably by poly(ADP-
ribosyl)ating Ku and decreasing in this way its affinity for double strand ends that 
otherwise would preclude proper DSB processing 259, 260, 261. The importance of 
understanding the role of PARP during HR was highlighted few years ago by the discovery 
that BRCA1- or BRCA2-deficient cancer cells are exquisitely sensitive to PARP inhibitors 
262, 263. Nowadays, PARP inhibitors are in clinical trials to treat BRCA-mutant breast and 
ovarian cancers. The accepted model to explain this synthetic lethality invokes the 
accumulation of unrepaired SSBs upon PARP inhibition, which results into one-ended 
DSBs upon collision with replication forks, and cell death in a HR-deficient background. 
Importantly, this therapeutic strategy is not confined to BRCA-deficient tumors and PARP 
inhibitors trigger synthetic lethality in other HR-defective cancers 264, 265, 266. In addition, 
the selective chemical ablation of crucial HR regulators, such as for cyclin-dependent 
kinase phosphorylation, can recapitulate a “BRCAness” phenotype, as demonstrated for the 
hypersensitivity of BRCA-proficient tumors to the combined CDK1/PARP inhibition 265. 
Moreover, PARP1 activity is constitutively enhanced in a HR-deficient context, thereby 
representing a good marker for the clinical outcome of the therapy 266.  
Interestingly, recent data showed that depletion of other SSBR crucial factors such as 
XRCC1 does not cause synthetic lethality with PARP inhibitors in BRCA-deficient cells, 
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thus challenging the SSB model of synthetic lethality. Instead, disabling the NHEJ pathway 
suppresses the specific killing of HR deficient cells by PARP inhibition, again suggesting a 
role of PARP1 in preventing the suppressive effect of NHEJ factors on HR after fork 
collapse 267. Understanding the exact mechanism of PARP1/HR synthetic lethality is 
particularly important to prevent the primary or acquired resistance of BRCA-mutant 
cancers to this treatment. In this context, resistance to PARP inhibitors was induced in a 
subset of BRCA1-deficient breast cancers by disabling 53BP1 expression, a crucial DNA 
damage response protein recently demonstrated to impede DNA resection at DSBs and to 
promote NHEJ over HR  268, 269. 
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2  MATERIALS AND METHODS 
	  
2.1 Antibodies and chemicals  
The antibodies used were rabbit polyclonal anti-PARP1 (ALX-210-302-R100) and 
mouse monoclonal anti-PAR (ALX-804-220-R100) from Enzo Life Sciences, rabbit 
polyclonal anti-PAR (4336-BPC-100) from Trevigen, mouse monoclonal anti-α−tubulin 
(T5168) and anti-FLAG M2 (F1804) from Sigma, rabbit polyclonal anti-53BP1 (NB100-
304) from Novus Biologicals, mouse monoclonal anti-γH2AX (05-636) from Millipore, 
mouse monoclonal anti-WRN (611169) from BD laboratories, rabbit polyclonal anti-BLM 
(ab476) from Abcam, mouse monoclonal anti-PARP1 (sc-8007), anti-Ku70 (sc-5309), anti-
Ku86 (sc-5280), anti-DNA-PKcs (sc-5282), anti-PCNA (sc-25280), rabbit polyclonal 
Glutation-S-Transferase (sc-459), anti-RAD51 (sc-8349), anti-TFIIH (sc-293), anti-
RECQ1 raised against aa 1-110 (sc-25547) were all from Santa Cruz, and a custom made 
rabbit anti-RECQ1 polyclonal antibody against a synthetic peptide of a unique sequence in 
the last 16 aa at the C-terminus of RECQ1 214 from Sigma.  
Nucleotide analogs (EdU, CldU and IdU), camptothecin (CPT), etoposide, methyl 
methanesulfonate (MMS), mitomycin-C (MMC), thymidine, nocodazole, propidium 
iodide, NAD+ and H2O2 were all from Sigma. The PARP1 inhibitors Olaparib was from 
Selleck Chemicals, NU1025 and 3-aminobenzamide (3-AB) were from Sigma. Protease 
inhibitor cocktail tablets were from Roche. All the radioactive reagents were from Perkin 
Helmer. 
 
2.2 Cell culture, transfections and synchronization  
Human Embryonic Kidney (HEK) 293 and 293T, human osteosarcoma (U-2 OS) and 
human cervical adenocarcinoma HeLa cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM, Gibco) supplemented with 10% (v/v) foetal calf serum (FCS, Life 
Technologies). 
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Cell transfections with plasmid DNA or siRNA duplexes were performed by using 
Nucleofector (Lonza) and HiPerFect (Qiagen), respectively, following manufacter’s 
instruction. Cell were analyzed 48-72 hours after transfection. 
U-2 OS cells were synchronized by double thymidine block and “mitotic shake-off” as 
previously described 270. Briefly, cells were synchronized at G1/S transition by a 2.5 mM 
thymidine treatment for 16 h, release in fresh medium for 10 h and again thymidine 
treatment for 16 h. Subsequently the cells were released from the block in fresh medium for 
the indicated time. For G2/M synchronization cells were released from thymidine block for 
4 hours in fresh medium and treated for 12 hours with 75 ng/ml nocodazole to trap mitotic 
cells; mitotic cells were collected by flask shaking-off. For G1 synchronization mitotic 
cells were replated and grown in fresh medium for 4 hours. 
 
2.3 Fluorescence-activated cell sorting (FACS) 
Cells were fixed in ice-cold 70% ethanol/PBS for 30 min. DNA was stained with 50 
µg/ml propidium iodide in PBS containing 0.1% Triton X-100 and 0.5 mg/ml DNase-free 
RNase A (Sigma). Samples were processed on a FACSCalibur flow cytometer equipped 
with CellQuest software (Becton Dickinson) and cell cycle profile distributions were 
determined with Modfit LT 3.0 software. 
 
2.4 Immunoblotting 
Total cell extracts were obtained by sonication in Lysis buffer (25 mM Tris-HCl pH 
7.5, 250 mM NaCl, 1 mM EDTA, 1 mM DTT, 20 mM NaF, 10 mM β-glycerophosphate, 
0.2 mM Na3VO4, 0.5% NP-40, 10% glycerol and protease inhibitors) or by directly 
scraping in SDS sample buffer (0.8% SDS, 4% glycerol, 280 mM mercaptoethanol, 25 mM 
Tris-HCl pH 6.8, 0.005% bromophenol blue). Protein concentration was measured by BCA 
assay (Pierce). Proteins were resolved by SDS-PAGE, transferred onto nitrocellulose 
(Protran) or PVDF (GE Healthcare) membrane and probed using the appropriate primary 
and secondary antibodies coupled to horse-radish peroxidase (Dako, Pierce). Protein 
detection was done with ECL reagents (GE Healthcare). 
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2.5 Protein complex purification 
To isolate protein complexes containing a RECQ1 bait protein, we prepared a stable, 
inducible HEK 293 cell line expressing a double tagged-version of the human RECQ1 
helicase by Flp recombinase-mediated integration. This system allows the generation of 
stable mammalian cell lines exhibiting tetracycline-inducible expression of a gene of 
interest from a single genomic location 271. The expression levels of the bait protein can be 
easily adjusted by tetracycline to levels that are comparable with corresponding 
endogenous protein levels. The protein complexes containing RECQ1 were isolated using a 
small double-affinity tag (SH-tag) consisting of a streptavidin-binding peptide and a 
hemagglutinin (HA) epitope tag. Following trypsin digestion, the samples were desalted 
and loaded directly onto a reverse-phase HPLC column coupled to a mass spectrometer. 
We performed three biological replicate SH-purification experiments, and analyzed each 
sample once by LC-MS/MS as already described 271. To eliminate co-purifying 
contaminant proteins, we generated a database of proteins identified from 3 independent 
SH–eGFP control purifications analyzed by LC-MS/MS. Proteins identified in bait-specific 
experiments that were also present in the contaminant database were considered as non-
specific binders and removed from the data set. Only the proteins specifically associated 
with the bait-RECQ1 protein in all three replicates were considered as significant. 
 
2.6 Immunoprecipitation  
HEK 293T or U-2 OS cells were treated as indicated, washed with ice-cold PBS and 
resuspended in cytoplasmic extraction buffer (10 mM Tris-HCl pH 7.9, 0.34 M sucrose, 3 
mM CaCl2, 2 mM magnesium acetate, 0.1 mM EDTA, 1 mM DTT, 20 mM NaF, 10 mM β-
glycerophosphate, 0.2 mM Na3VO4, 0.5% Nonidet P-40 and protease inhibitors) for 10 min 
at 4°C. Intact nuclei were pelleted by low-speed centrifugation, washed with cytoplasmic 
lysis buffer (without Nonidet P-40), lysed in nuclear lysis buffer (20 mM HEPES-KOH pH 
7.9, 150 mM KCl, 1.5 mM MgCl2, 20 mM NaF, 10 mM β-glycerophosphate, 0.2 mM 
Na3VO4, 10% glycerol, 0.5% Nonidet P-40 and protease inhibitors) by homogenization. 
DNA and RNA in the suspension were digested with 50 U/µl Benzonase (Sigma) at 4°C 
for 1 hour. In some experiments 50 µg/ml Ethidium bromide was added to nuclear lysate. 
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The nuclear soluble extract was clarified from insoluble material by centrifugation at 
20,000 × g at 4°C for 20 min, precleared with 50 µl protein A beads slurry (Santa Cruz) at 
4°C for 1 hour and incubated overnight with anti-RECQ1 (Sigma), anti-PARP1 (ALX-210-
302), or a control IgG rabbit polyclonal antibody (Santa Cruz) at 4°C. The 
immunocomplexes were captured by adding 50 µl of protein A beads slurry for 2 hours at 
4°C. After extensive washing with nuclear lysis buffer, proteins were eluted from beads 
with 2X SDS sample buffer at 95°C for 5 min, separated by SDS-PAGE and detected by 
immunoblotting with the appropriate antibodies. 
 
2.7 GST pull-down experiments  
Glutathione S-transferase (GST) and GST-fused wild-type and truncated RECQ1 
proteins were expressed in bacteria and purified according to a previously described 
procedure  272. Briefly, bacterial cultures harboring GST fused proteins were induced with 1 
mM isopropyl-β-D-thiogalactopyranoside (IPTG) overnight at room temperature. The 
pellets were resuspended in lysis buffer (50 mM Tris-HCl pH 8.0, 250 mM NaCl, 5% 
glycerol, 5 mM EDTA, 2 mM DTT, 1 mM PMSF and protease inhibitor) and sonicated. 
The cleared lysates were then loaded onto glutathione agarose beads (Sigma) and incubated 
for 1 h at 4ºC. Following incubation and extensive washing with lysis buffer, proteins 
immobilized on beads were resuspended at 50% (v/v) in the same buffer and kept frozen 
until use.  
We produced [35S]-labeled RECQ1 and [35S]-labeled PARP1 for in vitro binding assays by 
the TNT Reticulocyte Lysate System (Promega), using the corresponding pIRES FLAG-
Hemagglutinin (FH)-RECQ1 or PARP1 vector as template. 
Pull-down assays with GST-RECQ1 fragments were performed as previously described. 
Briefly, immobilized GST-fused RECQ1 fragments were pretreated with DNase I and 
RNase A for 30 min at 25ºC to remove bacterial nucleic acids. The beads were then washed 
twice with high salt solution (1 M NaCl) and equilibrated in binding buffer TNEN (20 mM 
Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF and 0.5 % NP-
40) supplemented with 0.1 mg/ml of ethidium bromide.  35S-methionine-labeled, in vitro-
translated PARP1 was incubated with GST-fusion RECQ1 fragments bound to 10 µl of 
glutathione–Sepharose beads (Amersham) in binding buffer TNEN (20 mM Tris–HCl pH 
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7.5, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF and 0.5 % NP-40) 
supplemented with 0.1 mg/ml ethidium bromide for 2 hours at 4°C. The beads were 
subsequently washed two times in ethidium bromide-supplemented TNEN buffer, and 
three times with TNEN buffer. Bound proteins were eluted with SDS sample buffer, 
resolved by gel electrophoresis, and visualized by direct autoradiography (Cyclon, GE 
Healthcare).  
For the production of GST-PARP1 fragments, HeLa cells (2 × 106 cells) were transfected 
by calcium-phosphate co-precipitation with 10 µg of recombinant DNA. Cells were lysed 
48 h later in lysis buffer (50 mM Tris–HCl pH 8.0, 250 mM NaCl, 0.5% NP-40, 0.5 mM 
PMSF and protease inhibitors). Lysates were cleared by centrifugation and incubated for 2 
hours with glutathione sepharose beads. Beads were washed 3 times with lysis buffer, 2 
times with lysis buffer adjusted to 1M NaCl and resuspended in GST binding buffer. Pull-
down experiments with the purified GST-PARP1 fragments and the 35S-methionine-
labeled, in vitro-translated RECQ1 was performed as described above. 
GST-pulldown experiments with GST-RECQ1 and purified recombinant PARP1 was 
performed as described above with some modification. Briefly, unmodified recombinant 
PARP1 (1 µg) or PARylated PARP1 (1 µg) were incubated with GST-RECQ1 (1 µg) or 
GST alone (1 µg), as a control. 100 µM NU1025 or 200 mM NAD+ were added as 
indicated. After incubation in binding buffer, the beads were washed with TNEN buffer 
containing 150 or 500 mM NaCl, as indicated. Bound proteins were eluted with SDS 
sample buffer, resolved by gel electrophoresis, and visualized by western blot with the 
appropriate antibodies. 
 
2.8 Purification of recombinant proteins  
Recombinant full-length RECQ1, RECQ1-ATPase mutants and PARP1 were 
expressed and purified from baculovirus/Sf9 cells as previously described in our laboratory 
135. The RECQ1-K119R and RECQ1-E220Q constructs were generated with the 
QuickChange XL site-directed mutagenesis kit (Strategene). The constructs of full length 
proteins and ATPase mutants were prepared in pFastBac LIC-Bse vectors, all of them with 
an N-terminal histidine tag. The recombinant bacmids were produced according to the 
manufacturer’s instructions using the modified pFastBac LIC-Bse transfer vector 
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(Invitrogen). SF9 cells were subsequently transfected with the recombinant bacmid DNA in 
order to produce the recombinant baculovirus expressing His6-tagged proteins. The 
baculovirus was used to infect Sf9 cells cultured in suspension on 27˚C. Three days after 
infection, cells were harvested by centrifugation, washed in cold PBS and then resuspended 
in lysis buffer (20 mM Tris-HCl pH 7.4, 400 mM KCl, 5 mM β-mercaptoethanol and 
protease inhibitor). For PARP1 purification 2 mM 3-AB was added to the lysis and wash 
buffer to prevent PARP1 activation during the purification procedure. The lysate was 
cleared by centrifugation (15000 r.p.m. at 4°C) and then incubated with TALON metal 
affinity resin (Clontech) (1 ml resin/5 mg protein) for 2 hours at 4°C. The resin was washed 
first with high salt buffer (20 mM Tris–HCl pH 7.4, 500 mM KCl, 5 mM β-
mercaptoethanol, 12.5 mM imidazole) for three times, and then equilibrated with low salt 
buffer (20 mM Tris–HCl pH 7.4, 100 mM KCl, 5 mM β-mercaptoethanol, 12.5 mM 
imidazole). The polyhistidine-tagged RECQ1 was eluted in buffer (20 mM Tris-HCl pH 
7.5, 100 mM NaCl, 5 mM β-mercaptoethanol, 120 mM imidazole). The purity of the 
protein was verified by SDS–PAGE.  
Recombinant E84A-WRN protein was kindly provided by Dr. Orren DK. 
 
2.9 In vitro poly(ADP-ribosyl)ation of PARP1 and  GST-RECQ1 
fragments 
Recombinant PARP1 (500 ng) was incubated in 20 µl of activity buffer (50 mM Tris-
HCl pH 7.5, 4 mM MgCl2, 50 mM NaCl, 200 µM DTT, 0.1 µg/µl BSA, 4 ng/µl DNaseI-
activated calf thymus DNA, and 400 µM NAD+) for 20 min at 37°C and the reaction was 
stopped by 100 µM NU1025 or 2 mM 3-AB.  
To test RECQ1 poly(ADP-ribosyl)ation, GST fusion proteins were incubated with 100 ng 
of recombinant PARP1 in activity buffer. After 10 min at 37°C, reactions were stopped by 
dilution in GST binding buffer supplemented with PARP inhibitor and washed extensively 
with the same buffer supplemented by 1M NaCl. The (ADP-ribosyl)ated products were 
resolved by gel electrophoresis and transferred to nitrocellulose membrane for visualization 
by western blot using an anti-PAR antibody. 
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2.10 Purified PAR production and PAR-binding assay  
PAR polymer was produced and purified as previously described 239. Briefly 
poly(ADP-ribosyl)ation reaction was set up as above and DNA digested for 30 min at 37°C 
by adding 10 U/ml of DNAseI (Fermentas) to the reaction. Next, 50 U/ml of proteinase K 
(Roche) and 1% SDS was added, followed by incubation for 1.5 hour at 55°C. After 
phenol–chloroform extraction, the water-soluble polymer was washed twice with diethyl 
ether, precipitated with ethanol, air-dried and dissolved in TBS (Tris-HCl pH 7.5, 150 mM 
NaCl). PAR concentration was determined spetrophotometrically using the following 
equation: [PAR] = (A258) cm-1/13,500 cm-1 M-1 
To perform PAR-binding assay, 2 pmol of recombinant proteins were spotted on a 0.2 µm 
pore size nitrocellulose membrane (Whatman) and air-dried. After extensively washing 
with TBS-T (TBS supplemented with 0.1% Tween-20) the membranes were incubated with 
100 nM PAR dissolved in 10 ml TBS-T for 1 hour at room temperature. Afterwards, the 
membranes were washed twice for 10 min with 10 ml TBS-T and three times for 10 min 
with TBS-T containing 1 M NaCl. The membranes were then blocked in TBS-T 
supplemented with 5% skim milk and developed by blotting with PAR antibody. 
Alternatively,  [32P]NAD+ was used as substrate in the poly(ADP-ribosyl)ation reaction and 
the membranes were developed by autoradiography (Cyclon, GE Healthcare).  
 
2.11 Isolation of proteins on nascent DNA (iPOND) 
iPOND assays were performed as recently described 273. Briefly 1 x 108 HEK 293T 
cells were pulse-labeled with 10 µM EdU for 20 min and treated as indicated. After cross-
linking with 1% Formaldehyde/PBS for 10 min at room temperature, cells are collected by 
scraping and washed twice with cold PBS. Collected cell pellets were frozen at -80°C, then 
resuspended in 0.25% Triton-X100/PBS and permeabilized for 30 min at room 
temperature. Pellets were washed twice with cold PBS and incubated at room temperature 
in click reaction buffer containing 10 µM biotin-azide, 10 mM sodium ascorbate and 2 mM 
CuSO4 in PBS, for 2 hours at a concentration of 1 x 107 cells per milliliter of click reaction 
buffer. DMSO was added instead of biotin-azide to the negative control samples (marked 
as no click). Cell pellets were washed twice with cold PBS, resuspended in lysis buffer 
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containing 50 mM Tris-HCl pH 8.0, 1% SDS, 1 µg/ml leupeptin and 1 µg/ml aprotinin, and 
sonicated by a Bioruptor sonicator (Diagenode) to generate DNA fragment sized ranged 
between 100-300 bp. Samples were centrifuged at 13,200 r.p.m. for 10 min and diluted 1:1 
(v/v) with PBS containing 1 µg/ml leupeptin and 1 µg/ml aprotinin. 50 µl streptavidin-
agarose beads (Novagen) were incubated with the samples overnight at 4°C in the dark. 
The beads were washed once with lysis buffer, once with 1M NaCl, and again twice with 
lysis buffer. Captured proteins were eluted and cross-links reversed in SDS sample buffer 
by incubating for 25 min at 95°C. Proteins were resolved on SDS-PAGE and detected by 
immunoblotting with the appropriate antibodies. 
 
2.12 Cell competition assays  
To study the response of RECQ1-depleted cells to specific genotoxic agents, we 
utilized a quantitative multicolor cell completion assay where RECQ1- or Luciferase 
(Luc)-depleted cells were mixed in equal amount with U-2 OS cells expressing dsRed 
following a previously described procedure 274. The mixed cells are treated with the 
specific DNA replication inhibitor or damaging agent, or left untreated. The relative 
sensitivity of the RECQ1-downregulated cells was then monitored by flow cytometric 
analysis of the ratio of uncolored RECQ1- downregulated cells to red fluorescence protein-
positive (RFP+) cells from three different experiments. 
 
2.13 Clonogenic assays 
Colony forming assays were conducted as already described 275. Briefly, Luc-siRNA or 
RECQ1-siRNA transfected U-2 OS cells were seeded at a dilution of 800 cells per well in 
six-well plates the day before treatment with the indicated drugs. Colonies formed after at 
least one week of growth were fixed with glutaraldehyde (6.0% v/v), stained with crystal 
violet (0.5% w/v) and	  counted using VersaDoc 4000 imaging system (BioRad). Colony 
forming efficiency was calculated following a procedure already published 275 from three 
different experiments. 
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2.14 DNA substrates 
All oligonucleotides were chemically synthesized and purified by reverse-phase high-
pressure liquid chromatography (RP-HPLC) (Intergrated DNA Tecnologies). Each 
nucleotide was then resuspended in Tris-EDTA (TE) buffer (10 mM Tris-HCl pH 7.5, 1 
mM EDTA). Oligonucleotide sequences used in branch migration and EMSA assays are 
reported in Table 2.1.  For each substrate, a single oligonucleotide was 5’-end-labeled with 
[γ-32P]ATP using T4 polynucleotide kinase (New England Biolabs). The kinase reaction 
was performed in PNK buffer (70 mM Tris-HCl pH 7.6, 10 mM MgCl2, 5 mM DTT) at 
37°C for 45 min and stopped by incubating at 70°C for 10 min for enzyme denaturation. 
For forked DNA intermediates, the [γ-32P]ATP-labeled or unlabeled oligonucleotides were 
respectively annealed to a 1.6-fold excess or an equal amount of the unlabeled 
complementary strands in annealing buffer (10 mM Tris-HCl pH 7.5, 50 mM NaCl) by 
heating at 95 °C for 8 min and then cooling slowly to room temperature. The purification 
of the forked duplex substrates was performed using Micro Bio-Spin columns (Bio-Rad), 
and analyzed on a 10% non-denaturing polyacrylamide gel run in TBE buffer (89 mM Tris-
borate pH 8.0, 2 mM EDTA).  
To prepare the branch migration substrates, [γ-32P]ATP-labeled and a 1.5-fold excess of 
unlabeled fork DNA intermediates were incubated in annealing buffer supplemented with 5 
mM MgCl2 for 30 min at 37oC, and then for an additional 30 min at room temperature.  
Holliday junction substrates were prepared by annealing the [γ-32P]ATP-labeled 
oligonucleotide to a 1.5 fold excess of the unlabeled three complementary strands in 
annealing buffer supplemented with 5 mM MgCl2 by heating at 95°C for 8 min and then 
slowly cooling to room temperature and purified by 5 ml of sepharose 4B column in TEN 
buffer (10 mM Tris HCl pH 8.0, 1 mM EDTA and 100 mM NaCl).  Various fractions were 
then eluted and analyzed on a 10% non-denaturing polyacrylamide gel run in TBE buffer. 
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Name Length 
(nt) 
Sequence 5’ à  3’ 
A 81 CTT TAG CTG CAT ATT TAC AAC ATG TTG ACC TTC AGT A/isodC/A ATC TGC TCT GAT GCC GCA TAG TGT CAT GCC AGA GCT TTG TAC 
B 81 CGG GTG TCG GGG CGC ATG ACA CTA TGC GGC ATC AGA GCA GAT TGT ACT GAA GGT CAA CAT GTT GTA AAT ATG CAG CTA AAG 
C 50 TCA GTA CAA TCT GCT CTG ATG CCG CAT AGT ATC ATG CGC CCC GAC ACC CG 
D 43 GTA CAA AGC TCT GGC ATG ATA CTA TGC GGC ATC AGA GCA GAT T 
E 49  






CCT GCA TAC AGA TGT TGA CCC AGC ACT GAC TAC TGT CGT CAA TCA 





CAC TGT GAT GCA CGA TGA TTG ACG ACA GTA GTC AGT GCT GCA GTG 





CAC TGT GAT GCA CGA TGA TCG ACG ACA GTA GTC AGT GCT GGG TCA 





GTG ATG ACA CCT GAC CAC TGC AGC ACT GAC TAC TGT CGT CGA TCA 





CAC TGT GAT GCA CGA TGA TCA GTG ACA GTA GTC AGT GCT GGG TCA 





GTG ATG ACA CCT GAC CAC TGC AGC ACT GAC TAC TGT CAC TGA TCA 
TCG TGC ATC ACA GTG 
L 50 GAC GCT GCC GAA TTC TGG CTT GCT AGG ACA TCT TTG CCC ACG TTG ACC CG 
M 50 CGG GTC AAC GTG GGC AAA GAT GTC CTA GCA ATG TAA TCG TCT ATG ACG TC 
N 50 GAC GTC ATA GAC GAT TAC ATT GCT AGG ACA TGC TGT CTA GAG ACT ATC GC 
O 50 GCG ATA GTC TCT AGA CAG CAT GTC CTA GCA AGC CAG AAT TCG GCA GCG TC 
 
Table 2.1 Sequences of the oligonucleotides used for substrate preparation. Bold red letters indicate 
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2.15 Electrophoretic mobility shift assay (EMSA) 
Purified proteins were incubated with 0.5 nM DNA in binding buffer containing 20 
mM Hepes-KOH pH 7.6, 75 mM KCl, 2 mM MgCl2, 2 mM ATPγS, 1 mM DTT, 0.25 mM 
EDTA, 20 µg/ml BSA, 5% glycerol, 0.1% NP-40 for 30 minutes at room temperature. 
When indicated 200 µM NAD+, 10 µM Olaparib and 100 nM PAR were added. Protein-
DNA complexes were resolved by electrophoresis on a 5% non-denaturing polyacrylamide 
gels in 0.5x TBE buffer for 3 hours at 4°C. Labeled DNA fragments were detected by 
autoradiography (Cyclon, GE Healthcare) and quantified as described previously 276. 
 
2.16 In vitro fork regression and restart assays  
Reactions were performed in a 20 µl of reaction mixture containing the indicated 
protein concentrations and 2 nM DNA substrate in branch migration buffer (35 mM Tris-
HCl pH 7.5, 20 mM KCl, 5 mM MgCl2, 0.1 mg/ml BSA, 2 mM DTT, 15 mM 
phosphocreatine, 30 U/ml creatine phosphokinase, 5% glycerol) at 37oC for the indicated 
times. The reaction was started by the addition of 2 mM ATP. For the poly(ADP-
ribosyl)ation experiments, the indicated concentrations of PARP1 and 200 µM NAD+, or 
100 nM purified PAR, were added to the reaction mixture without ATP and preincubated 
together with RECQ1 and the substrate at 37oC for 10 min. The reaction was then started 
by the addition of 2 mM ATP. DNA substrates were deproteinized by adding 3X stop 
reaction (1.2% SDS, 30% glycerol supplemented with proteinase K (3mg/ml)) and 
incubating at room temperature for 10 min prior to being resolved on an 8% non-
denaturing polyacrylamide gel run in TBE buffer at 4oC. Labeled DNA fragments were 
detected by autoradiography (Cyclon, GE Healthcare) and quantified as described 
previously 276. 
 
2.17 RECQ1, WRN and BLM downregulation, and RECQ1 
complementation assays  
siRNA-mediated transient downregulation of RECQ1 was achieved using 50 nM 
siRNA SMART pool against human RECQ1 (NM_032941, Dharmacon) in U-2 OS cells 
and a previously described protocol in which we established the specificity of the siRNA 
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pool 202, 214. siRNA-mediated transient depletion of WRN and BLM was achieved using the 
following siRNAs from Microsynth: siWRN (5'-UAGAGGGAAACUUGGCAAAdTdT-3') 
and siBLM (5'-CCGAAUCUCAAUGUACAUAGAdTdT-3'). shRNA-mediated 
downregulation was achieved by cloning the sequence targeting RECQ1 (5’- 
GAGCTTATGTTACCAGTTA-3’) into the pLKO.1 lentiviral shRNA expression vector. 
Virus was generated by transient co-transfection of pLKO.1 and the packaging plasmids 
psPAX2 and pM2D.G into HEK 293T cells. Viral supernatants were filtered through a 45-
µM filter and transduced on U-2 OS cells for 24 hours, followed by selection with 
puromycin (8µg/ml) for 3 days. Control transductions were performed using the pLKO.1 
vector expressing a shRNA targeting Luciferase (5’-ACGCTGAGTACTTCGAAATGT-
3’). The level of depletion was verified by western blot analysis. For the complementation 
assays we used a locally constructed RECQ1 RNAi-resistant open reading frame cloned 
into a pIRES vector under the control of the CMV promoter. Specifically, the nucleotides 
targeted by the RNAi (5’-GAGCTTATGTTACCAGTTA-3’) were partially substituted 
without changing the amino acidic sequence (5’-GTCACTATGCTATCAATTA-3’) by 
site-directed mutagenesis. Lentiviral depletion of endogenous RECQ1 was achieved using 
the protocol described above, and the resulting RECQ1-depleted cells were then 
nucleofected with a shRNA-resistant RECQ1 expression vector. Expression of the RNAi-
resistant, FLAG-tagged RECQ1 and K119R mutant was verified in control and RECQ1-
depleted cells by western blot analysis 48 hours after transfection. 
 
2.18 Microfluidic–assisted DNA fiber stretching and replication fork 
progression analysis 
Asynchronous U-2 OS cells were transiently transfected for 72 hours with siRNA 
SMART pools (or specific shRNA) against RECQ1 or Luciferase as reported earlier 202, 214. 
RECQ1- or Luciferase-depleted U-2 OS cells were labeled for 30 min each with 50µM 
CldU followed by 50 µM IdU. Cells were collected by trypsinization, and high molecular 
weight DNA from cells embedded in agarose plugs was isolated and stretched using a 
microfluidic platform as described earlier 277. For immunostaining, stretched DNA fibers 
were denatured with 2.5 N HCl for 45 min, neutralized in 0.1 M Na borate pH 8.0 and 
PBS, and blocked with 5% BSA/0.5% Tween-20/PBS for 30 min. Rat anti-CldU/BrdU 
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(ab6326, Abcam), goat anti-rat Alexa 594 (A11007, Invitrogen), mouse anti- IdU/BrdU 
(347580, BD Biosciences), and goat anti-mouse Alexa 488 (A11001, Invitrogen) 
antibodies were used to reveal CldU and IdU labeled tracts, respectively. A Leica SP5X 
confocal microscope was used to visualize the labeled tracts, and tract lengths were 
measured using the Image J software. Statistical analysis of the tract length was performed 
using Graphpad Prism. 
 
2.19 DSB detection by PFGE  
DSB detection by PFGE was performed in Massimo Lopes’s lab as previously 
described with minor modifications 278. Asynchronous subconfluent cultures of U-2 OS 
cells were harvested by trypsinization, and agarose plugs of 5 x 105 cells were prepared in a 
disposable plug mold (BioRad). Plugs were then incubated in lysis buffer (100 mM EDTA, 
1% (w/v) sodium lauryl sarcosyl, 0.2% (w/v) sodium deoxycholate, 1mg/ml proteinase K) 
at 37°C for 72 hours and washed four times in 20 mM Tris-HCl pH 8.0, 50 mM EDTA 
before loading onto an agarose gel. Electrophoresis was performed for 23 hours at 14°C in 
0.9% (w/v) Pulse Field Certified Agarose (BioRad) containing TBE buffer in a BioRad 
CHEF DR III apparatus, according to the following protocol (Block I: 9 hours, 120° 
included angle, 5.5 V/cm, 30- 18s switch; Block II: 6 hours, 117° included angle, 4.5 
V/cm, 18-9s switch; Block III: 6 hours, 112° included angle, 4.0 V/cm, 9-5s switch). The 
gel was then stained with ethidium bromide and analyzed using an Alpha Innotech Imaging 
system. DSB quantification was performed using ImageJ software, normalizing DSB 
signals to unsaturated signals of DNA trapped in the well (loading control). For each 
treatment, relative DSB levels were obtained comparing each treatment to the background 
DSB signals observed in untreated (NT) conditions. Mean and standard error of the mean 
(s.e.m.) values were obtained from three biological replicates of the same experiment. 
 
2.20 Immunofluorescence staining and analyses  
U-2 OS cells were grown on coverslips, fixed in 3.7% paraformaldehyde, 
permeabilized in 0.5% Triton X-100/PBS and blocked in 3% BSA/PBS. Coverslips were 
then stained with anti-53BP1 and anti-γH2AX primary antibodies and detected by 
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appropriate Alexa 488- and Alexa 594-conjugated secondary antibodies (Molecular 
probes). Toto3 Iodide (Life Technologies) was used as a nuclear counterstain. For RAD51 
and γH2AX double immunofluorescence, cells were extracted with cytoskeleton (CSK) 
buffer (10 mM Hepes-KOH pH 7.5, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2 and 
0.2% Triton X-100) for 5 min at 4°C to remove non-chromatin bound proteins and 
subsequently washed with cold PBS before fixation and staining with the appropriate 
antibodies. Cells were imaged using a Zeiss LSM 510 Meta confocal microscope. Images 
were acquired using the LSM 5 software. Foci were counted with ImageJ “Analyze 
particles” function or by direct visualization and “JACoP” plugin was used to calculate 
colocalization. The average number of foci was obtained from 3 independent experiments 
analyzing at least 60 (for 53BP1/ γH2AX) or 200 (for RAD51/ γH2AX) cells per sample. 
 
2.21 EM analysis of genomic DNA in mammalian cells  
In vivo psoralen cross-linking, isolation of total genomic DNA, and enrichment of the 
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3  RESULTS 
	  
3.1 RECQ1 interactome  
Recent studies point to an important, but yet not clearly defined, role of the human 
RECQ1 helicase in DNA replication and repair that is distinct from that of the other four 
human RecQ proteins 202. In order to better define the role of human RECQ1 helicase in 
DNA replication and repair, we first determined the composition of protein complexes 






FRT recombination  
































Figure 3.1. Expression of SH-tagged RECQ1 in HEK293T cells. (a) Schematic representation of 
the procedure followed for the generation of the inducible cell lines expressing a double-tagged 
version of human RECQ1. Isogenic cell lines were generated using Flp-recombinase-mediated 
integration into a single FRT site in Flp-in 293T-Rex cells that contain the genomic Flp-In site and 
a tet repressor (Invitrogen). (b) Isogenic bait protein expression in the presence and absence of 
1µg/ml tetracycline was visualized by indirect fluorescence microscopy with an anti-HA antibody. 
(c) Bait protein expression monitored by immunoblotting using an anti-HA antibody. 
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Total number of peptides 
Replicate 1 Replicate 2 Replicate 3 
RECQ1  
(RECQL) 291 289 275 
PARP1 
(PARP1) 18 13 12 
Ku70  
(XRCC6) 26 28 18 
Ku80  
(XRCC5) 28 19 14 
Histone H2A type 1-A 
(HIST1H2AA) 7 3 6 
Histone H2A type 2-A  
(HIST2H2AA4) 5 4 4 
Histone H2B type 1-L  
(HIST1H2BL) 9 8 9 
Histone 3.2 
(HIST2H3A) 2 2 2 
Figure 3.2. Purification of SH-tagged RECQ1 from HEK293 cells and mass spectrometry 
analysis of the RECQ1 complex. (a) Schematic representation of the purification procedure. (b) 
Western blot analysis of the SH-purification steps monitored using the anti-HA antibody. L: lysate; 
FTS: flow-through after streptavidin purification; ES: elution from streptavidin sepharose; FTH: 
flow-through after anti-HA purification; EH: elution form the anti-HA agarose (final eluate). (c) 
RECQ1 interacting proteins identified by mass spectrometry. We performed three biological 
replicate SH-purification experiments and analyzed each sample by LC-MS/MS. Only the proteins 
specifically associated with the bait-RECQ1 protein in all three replicates were considered as 
significant interacting proteins.  
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We generated a stable, inducible HEK 293 cell line expressing a doubly tagged-version of 
RECQ1, consisting of a streptavidin-binding peptide and a hemagglutinin tag, then isolated 
the protein complexes containing RECQ1 by affinity purification (Figure 3.1, 3.2a, 3.2b). 
The resulting protein complexes were then characterized by mass spectrometry profiling to 
identify RECQ1-associated proteins. Among the most abundant co-purified proteins were 
PARP1, Ku70 and Ku80, two key components of the DNA NHEJ repair pathway and 
several histone components (Figure 3.2c). In light of recent reports that suggest a role for 
PARP1 in the replication stress response 256, we decided to focus our next experiments on 
defining the role of the interaction between RECQ1 and PARP1. 
The RECQ1 interaction with PARP1 was confirmed by co-immunoprecipitation (Co-IP) 
experiments using nuclease-solubilized nuclear extracts from U-2 OS and HEK 293T cell 
lines, and an anti-RECQ1 antibody recognizing the last 16 aa at the C-terminus of RECQ1 
(aa 633-648). The same results were obtained using a different anti-RECQ1 antibody 
recognizing the first 110 aa at the N-terminus of the protein (data not shown). We also 
confirmed this interaction by parallel co-IPs using an anti-PARP1 antibody (Figure 3.3a). 
All co-IPs were performed in the presence of EtBr or Benzonase to make sure that the 
protein interaction was not DNA-mediated. Similar results were obtained using nuclear 
extracts from several additional cell lines, indicating that the association between RECQ1 
and PARP1 is not cell type-specific (data not shown). Moreover, we showed that RECQ1 
binds directly PARP1 by Far Western blot using the recombinant proteins, thus ruling out 
the possibility that other factors mediate this interaction in cells (Figure 3.3b). Our 
observation of a physical interaction between PARP1 and RECQ1 is also in agreement 
with previously published work that reported RECQ1 and PARP1 interact at viral 
replication origins 225, and with a study published while this work was in progress reporting 
an interaction between RECQ1 and PARP1 in human cells 280. 
Given the important role of RECQ1 during DNA replication, we decided to check whether 
this interaction is cell-cycle regulated. U-2 OS cells were synchronized at G1/S border by a 
double thymidine block, or at the beginning of mitosis by nocodazole treatment plus 
mitotic “shake-off”, and then released and collected at different time points. FACS analysis 
was employed to verify the synchronization procedure and the cell-cycle progression upon 
release (Figure 3.4c). Immunoprecipitation experiments performed on nuclear extracts 
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prepared collecting cells at different cell-cycle stages showed that the RECQ1-PARP1 
interaction in conserved throughout the cell-cycle and it is slightly increased at G1/S border 
(Figure 3.4b).  
Next, we performed new co-immunoprecipitation experiments treating cells with different 
DNA damaging agents. The results showed that the RECQ1-PARP1 interaction is 
markedly increased, particularly when using drugs that activate PARP1 such as CPT, MMS 
and H2O2 (Figure 3.5a and 3.8). 

























































Figure 3.3. RECQ1 interacts with PARP1. (a) IPs from HEK 293T cells using the anti-RECQ1 
or the anti-PARP1 antibody. Rabbit IgG IP served as a negative control. (b) Far Western analysis 
of the RECQ1-PARP1 interaction using purified recombinant proteins. Bovine Serum Albumin 
(BSA) and Proliferating Cell Nuclear Antigen (PCNA) were used as a negative control. 
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Figure 3.4. Cell-cycle dependence of RECQ1-PARP1 interaction. (a) and (b) Inpunts and IPs 
from double thymidine and “mitotic shake-off” synchronized U-2 OS  cells. Rabbit IgG IP served 
as a negative control. (c) FACS analysis confirms enrichment of cell-cycle-specific stages. 
 
There is growing evidences that the activity of PARP1 is important to build poly(ADP-
ribose) scaffolds on the chromatin surrounding a DNA lesion to allow the differential 
recruitment of protein complexes in the proximity of the damaged area 244. Thus, we 
decided to test if the RECQ1-PARP1 interaction is affected by the poly(ADP-ribosyl)ation 
of PARP1. By pretreating the cells with the specific PARP inhibitor NU1025 we were able 
to verify that the co-association of the two proteins is sharply reduced not only under 
normal conditions, but also upon DNA damage, suggesting that the poly(ADP-ribose) 
moieties synthetized by PARP1 on itself and on the damaged chromatin regulate the 
interaction with RECQ1, as previously demonstrated for other PARP1 binding partners 
(Figure 3.5a and 3.8).  
Results 
	  
	   62 
inputs 
CPT 

















































150 mM NaCl 
500 mM NaCl 
1    2   3   4    5   6    7   8   9   10    
c 
+   +    +    -     -    -     -    +    -    -          
 -   -     -    +     -    -    -     -    +    - 
-    -     -     -     +   +   +    -     -    + 
-    +    -     -     -    +    -    -    -    - 













Figure 3.5. RECQ1 interacts with poly(ADP-ribosyl)ated PARP1. (a) IPs from U-2 OS cells 
using the anti-RECQ1 antibody +/- PARP inhibitor (50 µM NU1025) and +/- DNA damage (100 
nM CPT for 2 hours). (b) Analysis of RECQ1-PAR binding in vitro. Proteins (2 pmol) were dot-
blotted onto a nitrocellulose membrane and incubated with 32P-labeled PAR, as described in the 
Material and Methods. BSA and PCNA were used as negative controls, while PARP1 and histone 
H1 were used as positive controls. (c) GST-pulldown experiments with unmodified recombinant 
PARP1 (1 µg) or PARylated PARP1 (1 µg) incubated with GST-RECQ1 (1 µg) or GST alone (1 
µg), as a control. 100 mM NU1025 or 200 mM NAD+ and 100 mM NU1025 were added as 
indicated. The interaction between RECQ1 and PARP1 is not affected by NU1025. However, the 
interaction of GST-RECQ1 with PARP1 is significantly decreased when the salt concentration in 
the washing buffer is increased from 150 to 500 mM, whereas the interaction with PARylated 
PARP1 is resistant to the washes with 500 mM NaCl. Bound proteins were resolved by gel 
electrophoresis, and visualized by western blot with anti-PAR, anti-PARP1 and anti-GST 
antibodies. The arrows point to the right signal for the indicated proteins. 
 
This notion was further supported by additional experiments using purified poly(ADP-
ribose) (PAR) in a dot-blot polymer assay. Recombinant proteins were dotted onto a 
nitrocellulose membrane, and their ability to bind 32P-radiolabeled PAR was measured 
(Figure 3.5b). The results showed that RECQ1 and the positive control Histone H1 
specifically interact with PAR despite bioinformatic analysis did not reveal any known 
PAR binding motif 281 or domain 244 in the RECQ1 sequence (data not shown). We next 
validated these observations using recombinant, purified PARP1 and GST-RECQ1. GST in 
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vitro pull-down confirmed that the interaction was direct, and significantly stronger when 
using a poly(ADP-ribosyl)ated form of PARP1 (Figure 3.5c). As a control, we also 
demonstrated that the interaction between recombinant RECQ1 and PARP1 was not 
affected by the addition of NU1025 indicating that the reduced RECQ1-PARP1 interaction 
detected in our co-IPs in the presence of NU1025 is due to the inhibition of PARP1 
poly(ADP-ribosyl)ation activity rather than to an effect of NU1025 on its conformation. 
Moreover, RECQ1 interaction with poly(ADP-ribosyl)ated PARP1 is resistant to high salt 
washing, while RECQ1-PARP1 binding is disrupted, supporting our conclusion that the 
PAR modification of PARP1 is important for strengthening the interaction with RECQ1 
(Figure 3.5c). 
We next mapped the domains of RECQ1 that interact with PARP1 and PAR using a 
series of GST-tagged RECQ1 fragments. These experiments showed that the same domain 
of RECQ1 involved in PARP1 recognition interacts with the PAR polymer. In particular, 
both PARP1 and PAR interact with the C-terminal fragment of RECQ1 (amino acids 391-
649) containing the Zn-binding and Winged Helix (WH) domains that form the so-called 
RQC domain, but not with the fragment 391-473 containing the Zn-binding domain alone. 
The fragment consisting of residues 474-649 that encompasses the WH domain is also able 
to interact with PARP1, although more weakly compared to fragment 391-649 (Figure 3.6c 
and 3.6e). This suggests that the deletion of residues 391-473 might affect the stability 
and/or conformation of the WH domain. In vitro poly(ADP-ribosyl)ation experiment also 
showed the same domain of RECQ1 involved in PARP1 and PAR binding is poly(ADP-
ribosyl)ated by PARP1 (Figure 3.7), although the biological relevance of this observation is 
limited by the fact that RECQ1 does not seem to be poly(ADP-ribosyl)ated in vivo (data 
not shown and as recently reported 280). 
To determine the region(s) of PARP1 involved in RECQ1 recognition, we generated 
corresponding GST-fusion proteins expressing truncated versions of PARP1 by 
overexpression and purification of each fragment from HeLa cells. Only the fragments 1-
371 and 384-524 were able to efficiently interact with RECQ1 by in vitro GST pull-down 
experiments. The fact that the fragment 174-366 did not pull-down RECQ1 indicates that 
the interaction is mediated by the first 173 N-terminal residues of PARP1 containing the 
DNA binding domain, and by residues 384-524 containing the BRCT domain of PARP1, 
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which is the automodification domain (Figure 3.5d). These two PARP1 domains are 
involved both in homodimerization 232, and in the binding of several partners including the 
































GST GST-RECQ1 1-281 























C D E F A B 
1014 




























































Figure 3.6. Structural determinants for the RECQ1-PARP1 interacion (a) and (b) Schematic 
representation of the domain structure of RECQ1 (D1 and D2, RecA-like domains; Zn, zinc-
binding domain; WH, winged-helix domain) and PARP1 (A, DNA binding domain; B, nuclear 
localization signal (NLS); D, BRCT automodification domain; E, contains a WGR motif; F, 
catalytic domain; FI and FII, zinc-finger motifs. A third zinc-finger motif has been recently been 
identified in domain C 282, 283). (c) Pulldown assays with GST-tagged RECQ1 fragments. Top: 
Coomassie stained gel of GST-tagged RECQ1 fragments. Bottom: autoradiography of in vitro GST 
pull-down assay using 35S-labeled in vitro-translated PARP1 protein. MW, molecular weight (kDa). 
(d) Pulldown assays with GST-tagged PARP1 fragments. Bound proteins were revealed by 
autoradiography (bottom panel). Purified GST or GST–PARP1 proteins were detected with an anti-
GST antibody (top panel).  (e) Analysis of PAR binding to GST-RECQ1 fragments (2 pmol) dot-
blotted onto a nitrocellulose membrane. The arrows indicate the two RECQ1 fragments that interact 
with 32P-labeled PAR. 
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Altogether, these results show that RECQ1 binds PARP1 and poly-ADP-ribose, and that 




























































Figure 3.7. RECQ1 is poly(ADP-ribosyl)ated in vitro. In vitro analysis of RECQ1 
poly(ADPribosyl)ation. GST-tagged RECQ1 fragments were incubated with PARP1 (1 µM) and 
200 µM of NAD+, and the presence of the PAR polymer was verified by Western analysis. The 
amount of PARP and GST-tagged RECQ1 fragments used in each experiment was also confirmed 
by Western analysis using anti-PARP1 and anti-GST antibodies, respectively. 
 
3.2 RECQ1-PARP1 interaction at damaged replication forks 
Our previous finding that RECQ1 associates with DNA replication origins in a cell-
cycle-regulated fashion pointed to a role for RECQ1 in DNA replication 202. Thus, we 
decided to investigate if RECQ1 associates with replicative factors by co-IP experiments. 
In addition to the previously identified interacting partners, we found that RECQ1 interacts 
with several MCM complex components in a DNA damage-dependent fashion, suggesting 
a possible involvement of RECQ1 at damaged replication forks. Again these interactions 
are lost upon PARP inhibition (Figure 3.8). The fact that these RECQ1-associated proteins 
were not detected by the mass spectrometry-coupled affinity purification could be due to 
the different procedure employed for the cellular extract preparation, or to a competition 
between the bait RECQ1 and the endogenous protein for binding to low abundant proteins. 
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Figure 3.8. RECQ1 interactome upon different DNA damage and PARP inhibition. IPs from 
U-2 OS cells using the anti-RECQ1 antibody ± PARP inhibitor (50 µM NU1025) and  ± DNA 
damage (2 mM MMS for 30 min, 100 nM CPT for 2 hrs; 2 µM MMC for 2 hrs; or 5 mM H2O2 for 
30 min). 






























Figure 3.9. DNA damage sensitivity of RECQ1 depleted cells. The Y-axis shows the relative 
survival of U-2 OS cells expressing a RECQ1 shRNA or Luc shRNA relative to dsRed-expressing 
U-2 OS cells, following treatment with HU (2 mM, 16 hrs), etoposide (ETOP, 1 µM, 16 hrs), CPT 
(10 nM, 24 hrs), MMC (750 nM, 1 hrs), MMS (1 mM, 1 hrs) and UV (20 J/m2). 
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Based on the recent discovery that PARP1 plays an important role in the reversal of 
replication forks after CPT treatment 117, we decided to investigate whether RECQ1 is also 
required for the cellular response to Top1 inhibition. First, we confirmed the previous 
observation that human cells depleted of RECQ1 have increased sensitivity to CPT 218. Cell 
competition analysis showed that RECQ1-depleted cells are only mildly sensitive to most 
replication inhibitors or DNA damaging agents apart from CPT and etoposide (ETOP) 
(Figure 3.9). Second, we exploited a new chromatin immunoprecipitation (ChIP) method to 
isolate proteins on nascent DNA (iPOND), in order to study the RECQ1-PARP1 
interaction in the context of ongoing DNA replication 273. Briefly, replicating HEK 293T 
cells were pulse-labeled (20 min) with the nucleotide analog EdU , CPT-treated and cross-
linked, as indicated in Figure 3.10a. After lysis and sonication, replicative chromatin was 
precipitated following biotin conjugation to EdU-labeled DNA by click chemistry, and a 
single-step of purification using streptavidin beads. Western blot analysis of recovered 
elutes confirmed that RECQ1 travels with the replisome under normal condition, 
expanding our previous finding that RECQ1 interacts with replication origins. Moreover, 
the RECQ1 binding on nascent DNA is significantly increased upon treatment with CPT, 
while the amount of the clamp loader PCNA is significantly decreased, in agreement with 
previous studies 284. More importantly, RECQ1 association with nascent DNA is sharply 
decreased by PARP inhibition (Figure 3.10b). We noticed that also PARP1 associates with 
nascent DNA in a poly(ADP-ribosyl)ation-dependent fashion, as we observed for RECQ1 
and in contrast to previous findings  256. This phenomenon might be explained by the 
biochemical nature of this protein whose activation decreases its DNA affinity, but, at the 
same time it is required to recruit other PARP1 molecules through interaction between the 
newly synthesized poly(ADP-ribose) chains and the BRTC domain of PARP, thus creating 
a positive feedback for PARP1 accumulation at DNA damage sites, as previously 
demonstrated in locally irradiated cells 285. Next, we confirmed these observation using a 
similar, but technically different, strategy where CldU-labeled replicative chromatin was 
isolated by a specific antibody to halogenated nucleoside analogs 256 (data not shown).  
Collectively, these results suggest that PARP1 activity is important for RECQ1 
































































Figure 3.10. RECQ1 associates with nascent DNA in a PARylation-dependent manner. (a) 
Schematic overview of the iPOND (isolation of protein on nascent DNA) procedure. Adapted from 
Sirbu BM., 2012 273. (b) iPOND analysis of proteins associated with CPT-damaged replication 
forks and PARylation dependence. U-2 OS cells were pulsed with EdU for 20 min and then 
collected or incubated with 100 nM CPT for 30 min. Olaparib was added 1 hrs before EdU labeling 
and maintained throughout the experiment where indicated. iPOND was performed as described in 
the Materials and Methods. The “No click” sample was treated with EdU only, but no biotin-azide 
was added during the click reaction.  
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3.3 RECQ1 catalyzes restoration of model replication forks in vitro 
Next, we tested whether recombinant RECQ1 mediates replication fork regression 
and/or restoration on synthetic DNA substrates. To measure these RECQ1 activities in 
vitro, we used a set of four oligonucleotides that can be annealed into two alternative ways 
that mimic model replication fork and “chicken-foot” structures, as previously described 
(Figure 3.11a) 90. The two terminal regions of the vertical arms contained different, 
complementary but mutually exclusive sequences to ensure that the “chicken foot” (or HJ 
structure) structure is converted to a replication fork structure and prevent complete 
separation of the two strands. In addition, we inserted a single isocytosine (iso-C) residue 
in the oligonucleotide that represents a replication fork leading strand and two mismatches 
on the substrate vertical arms to prevent spontaneous fork regression and restoration. These 
substrates allowed us to follow the branch migration activity of RECQ1 on a synthetic 
replication fork substrate, and to understand how the interaction of RECQ1 with PARP1 
affects the equilibrium between fork regression and restoration. Branch migration reactions 
were started by the addition of RECQ1, and performed as a function of time and protein 
concentration to investigate the kinetic and protein concentration dependence of the 
reaction. We found that RECQ1 promotes model replication fork restoration very 
efficiently and in a concentration-dependent fashion: more than 75 % of the chicken foot 
structure was converted into the model replication fork at 50 nM RECQ1 after 20 min 
(Figure 3.11b and 3.11c).  In contrast, RECQ1 was unable to catalyze the opposite reaction, 
fork regression even at the highest RECQ1 concentration. Identical results were obtained 
using a variant of the same substrate that lacks the 6 nt ssDNA gap on the leading strand 
template, thus ruling out the possibility that RECQ1 is unable to promote fork regression 
because of the presence of this single-stranded region at the junction (Figure 3.12a and 
3.12b). We observed that the poorly hydrolysable ATP analog ATPγS, or the non-
hydrolysable analog AMP-PNP, strongly inhibited the reaction, confirming that the 
ATPase activity of RECQ1 is essential to promote branch migration of the chicken foot 
structure and restoration of the active replication fork. The requirement for ATPase activity 
was also supported by the observation that two previously characterized ATPase-deficient 
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Figure 3.11. RECQ1 promotes in vitro fork restoration but not regression on synthetic DNA 
substrate. (a) Schematic of the procedure used for substrate preparation. Lined regions indicate 
heterologous sequences included in the vertical arms to prevent complete strand separation. In 
addition, a single isocytosine (iso-C) residue (denoted with a circle) and two mismatches (shown by 
carets) were introduced to prevent spontaneous substrate conversion. Oligonucleotide B was end-
labeled with [γ-32P]ATP (shown by a star). The sequence of all the oligonucleotides are reported in 
Table 2.1. (b) Fork restoration assays (lane 1-7) and fork regression assay (lane 8-14) performed 
using increasing RECQ1 concentrations (0, 15, 25, 35, 50, 100, and 200 nM) and a fixed 
concentration of the chicken foot substrate (2 nM, for restoration assay) or the replication fork 
structure (2 nM, for regression assay). All the reactions were stopped after 20 min. (c) Left, 
schematic of the reaction products. Right, percentage of the fork restoration and regression products 
plotted as a function of protein concentration. The data points represent the mean of three 
independent experiments. Error bars indicate s.e.m. 
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Figure 3.12. Fork restoration and regression assays using a DNA substrate that lacks a ssDNA 
gap on the leading strand template. (a) Fork restoration assays (lane 1-7) and fork regression 
assay (lane 8-14) performed using increasing RECQ1 concentrations (0, 15, 25, 35, 50, 100, and 
200 nM) and a fixed concentration of the chicken foot substrate (2 nM, for restoration assay) or the 
replication fork structure (2 nM, for regression assay). All the reactions were stopped after 20 min. 
(b) Left, schematic of the reaction products. Right, percentage of the fork restoration and regression 
products plotted as a function of protein concentration. The data points represent the mean of three 
independent experiments. Error bars indicate s.e.m. 
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Figure 3.13. Fork restoration and regression 
assays using non-hydrolysable ATP analogs or 
ATPase deficient RECQ1 mutants. Fork 
restoration and regression assays were performed 
in the presence of ATP or different ATP analogs 
using wild-type RECQ1 (lanes 2-5) or the 
ATPase deficient RECQ1 mutant, K119R (lane 
6) and E220Q (lane 7). The protein concentration 
was 50 nM for all the experiments. All the 
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On the basis of our results that RECQ1 interacts with PARylated PARP1 and the 
previous observations that the poly(ADP-ribosyl)ation activity of PARP plays a key role in 
mediating the accumulation of regressed forks after DNA damage 117, we examined the 
effect of PARylated PARP1 on the RECQ1 fork restoration activity. We found that 
PARylated PARP1 strongly inhibited fork restoration rates of RECQ1: approximately 80 % 
of the chicken foot structure was converted within 20 min into a replication fork structure 
using 40 nM RECQ1. This fraction of restored fork structures was reduced to <30% by an 
equimolar concentration of PARylated PARP1 (Figure 3.14). Experiments performed at 
increasing PARylated PARP1 concentrations showed that the maximal inhibition was 
already achieved at equimolar concentrations since no further inhibition was observed by 
using a 2-fold excess of PARylated PARP1 (Figure 3.15).  
Additional experiments using other four-ways junction substrates with heterology regions 
of 1 and 4 bases (Figure 3.16a), confirmed that RECQ1 has a strong branch migration 
activity and that its helicase activity may be used to bypass regions of heterology. 
However, we observed a 3-4-fold decrease in the formation of the branch migration 
product when the heterology region was increased from 1 to 4 bases (Figure 3.15b, 3.15d). 
PARylated PARP1 inhibited RECQ1 branch migration activity on these substrates, as 
previously observed with the replication fork substrates (Figure 3.15c, 3.15e).  
Importantly, this conclusion was also supported by additional fork restoration assays 
performed using purified poly(ADP-ribose) (PAR), instead of PARylated PARP1, 
confirming that the interaction of RECQ1 with PAR is responsible for the inhibition of the 
fork restoration activity (Figure 3.14).  
In agreement with previous findings 234, EMSA experiments using no-moveable HJ as 
a probe confirmed that PARylated PARP1 binds DNA with very low affinity because of 
the electrostatic repulsion between DNA and highly negative charged PAR, ruling out the 
possibility that the inhibitory effect of PARylated PARP1 on RECQ1 activity is due to a 
competition for DNA binding (Figure 3.17).  Furthermore, to gain more insight into the 
mechanism for PAR-mediated RECQ1 inhibition, we tested whether PARylated PARP1 
and PAR influence the ability of RECQ1 to bind DNA. Our results showed that poly(ADP-
ribosyl)ated PARP1 and PAR inhibit RECQ1 affinity for HJ in a concentration–dependent 
manner, and again this effect is not related to a competition for DNA (Figure 3.18). 
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Interestingly, this inhibitory effect is more evident on high-order molecular species of 
RECQ1 bound to the DNA, thus suggesting that PAR might prevent the binding of RECQ1 
oligomers on branched DNA structures. However, PAR does not seem to inhibit the 
ATPase activity of RECQ1 in the presence of ssDNA, HJ, and fork substrates (data not 
shown).  
The ability of RECQ1 to promote fork restoration is not unique for this helicase. 
Previous studies using the same substrate showed that the human BLM helicase and 
RAD54, a member of the SNF2 family of DNA-dependent ATPases, catalyze both fork 
restoration and regression, with a bias toward fork restoration  90. 
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Figure 3.14. Inhibition of in vitro fork restoration activity of RECQ1 by PARylated PARP1 
and PAR. (a) Kinetic experiments using RECQ1 (40 nM) and the chicken foot substrate (2 nM), 
visualized by gel electrophoresis and autoradiography. Lanes 1-7, RECQ1 alone; lanes 8-14, 
RECQ1 in the presence of PARylated PARP1 (40 nM); lanes 15-21, RECQ1 in the presence of 
PAR (100 nM). (b) Left, schematic of the reaction products. Right, percentage of the fork 
restoration products for RECQ1 alone and RECQ1 in the presence of PARylated PARP1 or PAR 
plotted as a function of time (min). The data points represent the mean of three independent 
experiments. Error bars indicate s.e.m.  
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Figure 3.15. Inhibition of the in vitro fork restoration activity of RECQ1 by increasing 
concentrations of PARylated PARP1. Top, fork regression assay using a fixed concentration of 
chicken foot substrate (2 nM) and visualized by gel electrophoresis and autoradiography. Lanes 1, 
substrate alone; lane 2, RECQ1 alone (50 nM); lanes 3-10, fork restoration assays performed using 
increasing PARylated PARP1 concentrations (3.125, 4.16, 6.25, 12.5, 16.6, 25, 50 and 100 nM) and 
a fixed concentration of RECQ1 (50 nM); lane 11, PARylated PARP1 alone (100 nM). All the 
reactions were stopped after 20 min. Bottom, percentage of the fork restoration products plotted as 
a function of PARylated PARP1 concentration. The data points represent the mean of three 
independent experiments. Error bars indicate s.e.m. 
 
This equilibrium was dramatically shifted by RAD51 that inhibits the fork restoration and 
stimulates fork regression activity of RAD54, but not of BLM.  In addition, the human 
WRN helicase was previously shown to promote both regression and re-establishment of 
model replication forks in vitro 153, 182. These results were confirmed by our experiments 
using the exonuclease-deficient WRN-E84A mutant that allows following the branch 
migration reaction without possible complications arising from the substrate digestion. 
WRN-E84A was able to promote both reactions with similar efficiency, with a slight bias 
toward fork restoration (Figure 3.19a). Furthermore, the fork restoration activity of WRN-
E84A was not inhibited by the presence of PARylated PARP1, in agreement with previous 
studies performed using a different set of substrates 189 (Figure 3.19c). Collectively, these 
results show that although other helicases or translocases are able to promote fork 
restoration and regression, RECQ1 has a striking preference to promote fork restoration 
versus regression, and its activity is uniquely regulated by PARylated PARP1. 
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Figure 3.16. Effect of PARylated PARP1 on RECQ1 branch migration activity using the HJ 
substrate. (a) Schematic representation of the Holliday junction (X-junction) substrates used for 
the branch migration assays; HJ(1) and HJ(4) contain 1 or 4 base of heterology (shown by carets), 
respectively. The sequence of all the oligonucleotides are reported in Table 2.1. (b) Lanes 1-3, 
DNA migration markers; lanes 4-9, branch migration assays performed using increasing RECQ1 
concentrations (0, 25, 35, 50, 100, and 200 nM) and a fixed concentration of HJ(1) substrate (2 
nM); lanes 10-15, branch migration assays using increasing RECQ1 concentrations (0, 25, 35, 50, 
100, and 200 nM) and a fixed concentration of the HJ(4) (2 nM). (d) Percentage of the branch 
migration products plotted as a function of protein concentration. The data points represent the 
mean of three independent experiments. Error bars indicate s.e.m. (c) Lanes 1-7, kinetic 
experiments performed using 50 nM RECQ1 and a fixed concentration of HJ(1) substrate (2 nM); 
lanes 8-14, kinetic experiments performed in the presence of 50 nM RECQ1, PARylated PARP1 
(50 nM) and a fixed concentration of HJ(1) substrate (2 nM). (e) Percentage of the branch 
migration products for RECQ1 alone and RECQ1 in the presence of PARylated PARP1 plotted as a 
function of time (min). The data points represent the mean of three independent experiments with 
the standard deviation indicated by error bars. 
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Figure 3.17. DNA binding assays at increasing protein concentrations using the HJ probe. 
EMSA experiments performed using a “non-moveable” HJ substrate with a 12-bp homologous core 
(0.5 nM). Lane 1, substrate alone; lanes 2-7, experiments at increasing RECQ1 (a), PARylated 
PARP1 (b), and PARP1 (c) concentrations (1, 2, 5, 12, 25, 50 nM). (d) The plots are the average of 
three independent experiments. Error bars indicate s.e.m.  
PARylatedPARP1 PAR 
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Figure 3.18. PARylated PARP1 or PAR inhibition of RECQ1 binding to DNA. EMSA 
experiments performed using a “non-moveable” HJ substrate with a 12-bp homologous core (0.5 
nM). Lane 1, substrate alone; lane 3, 20 nM RECQ1 alone; lanes 3-7, experiments at increasing 
PARylated PARP1 (5, 12, 25, 50 nM) and PAR (25, 50, 100, 200 nM) concentrations.  
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Figure 3.19. Fork restoration and regression assays using human WRN. (a) These experiments 
were performed using exonuclease-deficient WRN-E84A mutant that allows following the branch 
migration reaction without possible complications arising form the substrate digestion. Lanes 1-7, 
fork restoration assays performed at increasing WRN-E84A concentrations (0, 0.9375, 1.875, 3.75, 
7.5, 15, and 30 nM) and a fixed concentration of the chicken foot substrate (2 nM); lanes 8-14, fork 
regression assays at increasing WRN-E84A concentrations (0, 0.9375, 1.875, 3.75, 7.5, 15, and 30 
nM) and a fixed concentration of the replication fork structure (2 nM). All the reactions were 
stopped for 20 min. (b) Left, schematic of the reaction products. Right, percentage of the fork 
restoration and regression products plotted as a function of protein concentration. The data points 
represent the mean of three independent experiments. Error bars indicate s.e.m. (c) Fork restoration 
assays performed in the presence (lanes 2, 4, 6) and absence (lanes 1, 3, 5) of PARylated PARP1 
(50 nM) using wild-type RECQ1 (50 nM; lanes 3, 4) or WRN-E84A (20 nM; lane 5, 6). All the 
reactions were stopped for 20 min.  
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3.4 RECQ1 depletion makes PARP activity dispensable to promote 
CPT-induced replication fork slowing and prevent DSB 
accumulation 
Next, we decided to test if RECQ1 depletion affects the rates of replication fork 
progression upon Top1 inhibition in a cellular context using genome-wide single-molecule 
DNA replication assays. We pulse-labeled U-2 OS cells with the thymidine analog CIdU 
(red label) for 30 min, then treated cells with 50 nM CPT and concomitantly labeled them 
with the second thymidine analog, ldU (green label), for an additional 30 min (Figure 
3.20a). The IdU tract length distributions were then analyzed after CPT treatment with or 
without PARP inhibition. Using this approach, we initially confirmed the previous findings 
that replication forks rapidly slow upon treatment with low CPT doses (50 nM), and that 
this effect requires the action of the poly(ADP-ribose) polymerase 1 (PARP1) 117. This is 
consistent with the notion that PARP inactivation does not perturb normal fork progression, 
but prevents fork slowing after Top1 inhibition. Next, we looked at the rates of fork 
progression in RECQ1-depleted cells treated with CPT and the clinically useful PARP 
inhibitor Olaparib. Our results showed that PARP inhibition did not rescue CPT-induced 
fork slowing in RECQ1-deficient cells (Figure 3.20b and 3.20c).  
These results identify an essential role of RECQ1 in the control of fork progression upon 
Top1 inhibition. Analogous results were obtained using a U-2 OS cell line where 
endogenous RECQ1 is efficiently downregulated by lentiviral expression of a RECQ1 
shRNA with a different RNAi sequence (figure 3.21b), confirming that the observed effect 
is specifically associated with RECQ1 loss, and not simply due to an unspecific RNAi 
outcome (Figure 3.21c). This notion was further validated by complementation assays in 
RECQ1-depleted cells rescued with an shRNA-resistant version of the RECQ1 protein 
(Figure 3.22b). The complementation of RECQ1-depleted U-2 OS cells with shRNA-
resistant wild type RECQ1 abrogated the effect of RECQ1 depletion on replication fork 
progression upon Top1 inhibition. Moreover, the complementation of RECQ1-depleted 
cells with the ATPase deficient RECQ1 mutant (K119R) confirmed that the 
ATPase/helicase activity of RECQ1 is essential for its role in replication fork progression 
upon Top1 inhibition, as already inferred from the biochemical studies (Figure 3.21c and 
3.21d). Additional DNA fiber experiments with BLM- and WRN-depleted cells showed 
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that, in contrast to the results obtained with RECQ1-depleted cells, PARP inhibition was 
still able to abrogate CPT-induced fork slowing in the absence of these two helicases 
(Figure 3.22). These results strongly support the notion that the identified role of RECQ1 in 
the control of fork progression upon Top1 inhibition reflects a specific function of RECQ1 
and not a more general role of the RecQ helicase family members.  
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Figure 3.20. Restoration of normal replication fork progression after Top1 and PARP 
inhibition is impaired in RECQ1-depleted U-2 OS cells. (a) Top, schematic of single DNA fiber 
replication track analysis. U-2 OS cells were transfected with siRNA against Luciferase (siLuc) or 
RECQ1 (siRECQ1) before CldU or IdU labeling, as indicated. Red and green denote CldU- and 
IdU-containing tracts, respectively. CPT (50 nM) was added concomitantly with the second label. 
Bottom, representative DNA fiber tracts from Microfluidic-assisted replication tract analysis of 
RECQ1 depleted U-2 OS cells upon Top1 and/or PARP inhibition. Scale bar, 12.5 µm. (b) 
Statistical analysis of IdU tract-length measurements from Luc- or RECQ1-depleted cells. Relative 
length of IdU tracts synthesized after mock (NT) or CPT treatment (50 nM). At least 175 tracts 
were scored for each dataset. Olaparib (OLA, 10 µM) was optionally added 2 hours before CldU 
labeling and maintained during labeling. Whiskers indicate the 10th and 90th percentiles. ns, not 
significant; **p<0.006,   **** p<0.0001 (Mann-Whitney test). (c) Smoothed histogram of IdU 
tract-length distribution after Top1 and/or PARP inhibition in RECQ1-depleted cells. (d) RECQ1 
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Figure 3.21. Genetic complementation of RECQ1-depleted cells with wild-type RECQ1, but 
not with the ATP-deficient K119R mutant, rescues the fork progression phenotype observed 
in RECQ1-depleted U-2 OS cells. (a) Experimental scheme for genetic knockdown-rescue 
experiments. U-2 OS cells were transduced with lentivirus to Luciferase (shLuc) or RECQ1 
(shRECQ1). RECQ1-depleted cells were nucleofected to express RNAi resistant wild-type 
(RNAiR-wt) and ATPase-deficient (RNAiR-K119R) RECQ1 before CldU labeling. (b) Western 
blot analysis of RECQ1-depleted cells (shRECQ1) complemented with the shRNA resistant wild 
type RECQ1 or K119R mutant (both proteins are FLAG-tagged). Tubulin was detected as a loading 
control (c) Statistical analysis of IdU tract length measurements from a. Relative length of IdU 
tracts synthesized after CPT treatment (50 nM). At least 175 tracts were scored for each dataset. 
Olaparib (OLA, 10 µM) was optionally added 2 hours before CldU labeling and maintained during 
labeling. Whiskers indicate the 10th and 90th percentiles. ns, not significant; **p<0.006,   **** 
p<0.0001 (Mann-Whitney test).  (d) Smoothened histogram of IdU tract-length after Top1 and 
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Interestingly, there was a minor, but statistically significant, difference between the mean 
length of the replication tracts measured in the untreated RECQ1-depleted cells relative to 
the untreated control cells (siLuc). This is in line with our previous studies where we 
observed that the replication tracts were slightly shorter in RECQ1-depleted cells versus 
controls in the absence of DNA damage 202. These data suggest that RECQ1 may play an 
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Figure 3.22. Restoration of normal replication fork progression after Top1 and PARP 
inhibition is not impaired in WRN- or BLM-depleted U-2 OS cells. Top, WRN and BLM 
expression after siRNA knockdown, detected by western blotting. Transcription factor II H (TFIIH) 
was detected as loading control. Bottom, statistical analysis of IdU tract-length measurements from 
siLuc-, WRN- and BLM-depleted cells. Relative length of IdU tracts synthesized after mock (NT) 
or CPT treatment (50 nM). At least 175 tracts were scored for each dataset. Olaparib (OLA, 10 µM) 
was optionally added 2 hours before CldU labeling and maintained during labeling. Whiskers 
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PARP inhibition prevents CPT-induced fork slowing, and results in detectable 
chromosomal breakage at low CPT doses 117. Thus, we decided to determine whether 
RECQ1 depletion also influences DSB accumulation after CPT using a recently optimized 
Pulsed Field Gel Electrophoresis (PFGE) protocol 117. Our PFGE analysis confirmed that 
PARP inhibition in U-2 OS cells leads to the induction of high levels of DSBs after CPT 
treatment (100nM) (Figure 3.23a and 3.23b). These results are consistent with the notion 
that PARP-inhibited or defective cells do not slow or accumulate reversed forks after CPT 
treatment, leading to replication run-off at Topoisomerase I cleavage complexes (Top1cc) 
and DSB formation even at low CPT doses 117. RECQ1 depletion, on other hand, had the 
opposite effect: fork slowing after CPT is not rescued by PARP1 inhibition, and DSB 
induction by PARP inhibitors is suppressed in RECQ1-depleted cells (Figure 3.23a and 
3.23b).  
As an alternative method to monitor DSB formation, we looked at γH2AX and 53BP1 foci 































































Figure 3.23. PARP inactivation leads to DSB formation at low CPT doses in the presence but 
not in the absence of RECQ1. (a) PFGE of U-2 OS cells transfected with  siLuc or siRECQ1, 
untreated (NT) or treated with CPT (100 nM) and/or Olaparib (OLA, 10 µM). Ionizing radiation 
(IR)-treated cells was used as positive control. (b) DSB signals quantified by ImageJ and 
normalized to unsaturated signals of DNA retained in the wells. Values obtained from each 
treatments were then normalized against their respective untreated controls to obtain the fold 
change in DSBs upon treatment with CPT. Results from three independent experiments; *p<0.05 
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In agreement with previous findings, we found that only a minor fraction of γH2AX foci 
colocalized with 53BP1 upon 100 nM CPT treatment and that PARP inhibition led to a 
considerably higher degree of colocalization of γH2AX and 53BP1 117 (Figure 3.24a and 
3.24b). However, RECQ1 depletion reduced the fraction of colocalizing foci in the 
presence of Olaparib, supporting the notion that DSB induction by PARP inhibitors is 
suppressed in RECQ1-depleted cells. Collectively, these data indicate that RECQ1 
regulates the rate of replication fork progression and that RECQ1 depletion makes PARP 
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Figure 3.24. PARP inactivation leads to DSB0 formation at low CPT doses in the presence, 
but not in the absence of RECQ1. (a) Representative images of immunofluore cence in U-2 OS 
cells transfected with siLuc or siRECQ1, untreated or treated with CPT (100 nM) and/or Olaparib 
(10 µM), and stained for γH2AX and 53BP1. Nuclei were stained with Toto3 and merged 
fluorescence images are shown (b) Average number of γH2AX foci per cell and the average 
fraction (shaded) of γH2AX foci colocalizing with 53BP1. At least 35 cells were scored for each 
dataset. Error bars, s.e.m. 
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3.5 RECQ1 is essential for fork restart upon Top1 poisoning 
The fact that RECQ1 loss makes PARP activity dispensable to prevent fork slowing 
and DSB formation in CPT-treated cells suggests that there may be accumulation of 
regressed forks in RECQ1-depleted cells 117. This is in agreement with our biochemical 
results that suggest a role for RECQ1 in regressed fork restart. In order to provide more 
direct evidence for this idea we used electron microscopy (EM), one of the most powerful 
techniques to visualize the fine architecture of in vivo replication intermediates  279. 
Previous EM analysis of replication intermediates showed that replication forks undergo 
rapid fork reversal upon Top1 inhibition 117. Furthermore, PARP1 activity has been shown 
to be required for effective fork reversal, possibly by promoting the 
accumulation/stabilization of regressed replication forks and thus preventing fork collision 
with a CPT-induced lesion to generate a DSB. To test the hypothesis that there might be an 
accumulation of reversed forks in RECQ1-depleted CPT-treated cells, we performed EM 
experiments using RECQ1-depleted CPT-treated U-2 OS cells with or without PARP 
inhibition (Figure 3.25a and 3.25b). Consistent with previous findings, we observed a high 
frequency of fork reversal (approximately 30% of molecules analyzed) in U-2 OS cells 
transfected with a control (siRNA-Luc) siRNA and treated with 25 nM CPT. The same 
experiments performed in the presence of Olaparib confirmed that PARP inhibition in 
control cells markedly decreased the fraction of reversed forks from 30% to less than 10%. 
RECQ1 depletion upon CPT treatment resulted in a higher frequency of fork reversal 
events (approximately 44%) than in control cells. Most importantly, PARP inactivation in 
RECQ1-depleted cells did not result in a marked reduction in the fraction of regressed 
forks, suggesting that regressed forks are not restarted in the absence of PARP activity 
upon RECQ1 inactivation. To test this hypothesis directly, we performed recovery 
experiments and measured reversed fork frequency after CPT removal. While in control 
cells drug removal resulted in a marked decrease in the frequency of fork reversal (from 30 
to 10%), RECQ1-depleted cells maintained a high frequency of reversed forks 
(approximately 33%) 3 hours after CPT withdrawal. These data strongly suggest that 
RECQ1 is needed to restart reversed forks and indicate that PARP requirement to observe 
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Figure 3.25. Reversed forks accumulate and are unable to restart in RECQ1-depleted cells 
after CPT treatment. (a) Representative electron micrograph of a reversed fork observed on 
genomic DNA from U-2 OS cells transfected with siRECQ1 and treated with CPT (25 nM) and 
Olaparib (10 µM). The white arrow points to the four-way junction at the replication fork. D = 
Daughter strand, P = Parental strand, R = Reversed arm. (b) Left, frequency of fork reversal in U-2 
OS cells transfected either with siLuc or siRECQ1 and treated with CPT and/or Olaparib (OLA). 
Restart experiments measuring the frequency of fork reversal were performed 3 hours after CPT 
removal. Numbers above bars indicate proportion of reversed forks as a percentage of total number 
of molecules (bottom, parentheses). Right, RECQ1 expression after siRNA knockdown detected by 
western blotting. TFIIH was detected as loading control. 
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3.6  Role of Homologous Recombination in the restart of CPT-damaged 
replication forks upon RECQ1 depletion and/or PARP1 inhibition 
DSBs are the major cellular events leading to cell death following DNA replication 
stress. On the basis of our discovery that PARP1 activation prevents DSB formation upon 
CPT treatment by limiting RECQ1-mediated fork restart, we would predict that RECQ1 
depletion should partially rescue the cellular hypersensitivity to combined Top1 and PARP 
inhibition. Unexpectedly, PARP inhibition results in an increased CPT sensitivity of 
RECQ1-depleted U-2 OS cells relative to the control measured by colony forming assays 
(Figure 3.26). 
In order to better understand the molecular basis of this result, we first analyzed the 
formations of RAD51 foci on γH2AX-positive cells by indirect immunofluorescence. 
Homologous recombination is the elective pathway that cells use to deal with replicative 
damage, and HR-defective cells are extremely sensitive to Top1 inhibition 286. The 
formation of long RAD51 nucleofilaments (several kilobases) during the first step of HRR 
results in chromatin-associated foci that can be cytologically detected and quantified as 
read-out of ongoing recombination repair 287. On the other hand, DSB-independent 
assembly of RAD51 on DNA, as in the case of stalled replication fork protection, does not 
trigger visible foci formation, perhaps because of the shorter nature of the RAD51-ssDNA 
filament (less than 1 kilobase) 258. Our immunofluorescence analysis showed that the short 
treatment (1 hour) with low doses of CPT (25 nM and 100 nM) used in this study trigger 
only a moderate increase of RAD51 foci in siLuc-transfected U-2 OS cells, confirming 
again the notion that there is a low level of DSBs generated by clinical relevant CPT doses 
under normal conditions. In contrast, RECQ1 depletion leads to a significant increase in 
RAD51 foci (Figure 3.27a), particularly in the experiment performed 3 hours after removal 
of CPT (Figure 3.27b). These evidences challenge the dogma that RAD51 foci are strictly 
associated with DSB repair centers during S-phase (see Discussion).  
On the other hand, CPT-induced RAD51 foci markedly decreased both in wild type and 
RECQ1-depleted cells upon PARP inhibition. Interestingly, PARP1 is known to be 
implicated in Mre11-mediated DNA resection and RPA/RAD51 foci formation upon DSB 
formation induced by long HU exposure (12-24 hours) 256. Collectively, these findings 
indicate that RECQ1 is important to restart CPT-induced regressed forks in a non-
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recombinogenic way, whereas its depletion leads to RAD51-mediated processing of these 
replicative structures. The role of PARP1 in this process is more intricate: in a first attempt, 
its PARylation activity coordinates the processes of fork reversal to avoid DSB formation 
by controlling the non-recombinogenic RECQ1-mediated restart of CPT-damaged forks; if 
this mechanism fails (as in the absence of RECQ1), PARP1 might be required for the 
proper establishment of HR-mediated replication fork repair/restart. Intriguingly, PARP1 
activity is enhanced in RECQ1 depleted cells both under genotoxic stress and normal 
conditions (data not shown). Further experiments will be necessary to elucidate the role of 
PARP1 in this context and clarify the molecular basis of the synergistic toxicity of PARP 
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Figure 3.26. CPT sensitivity of RECQ1 depleted and/or PARP1 inhibited U-2 OS cells. The Y-
axis shows colony formation efficiency (percentage) of U-2 OS cells expressing a RECQ1 shRNA 
or Luc shRNA relative to untreated control following treatment with CPT (25 or 100 nM, 16 hrs) 
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Figure 3.27. RAD51 and γH2AX colocalization at CPT-damaged replication forks upon 
RECQ1 depletion and/or PARP1 inhibition. (a) Representative images of immunofluorescence 
in U-2 OS cells transfected with siLuc or siRECQ1, untreated or treated with 25 (not shown) or 100 
nM CPT for 1 hour, with 10 µM Olaparib or DMSO and stained for chromatin-bound γH2AX and 
RAD51 after detergent extraction and fixation. Nuclei were stained with Toto3 and merged 
fluorescence images are showed. (b) Results show the percentage of γH2AX positive cells and the 
RAD51/γH2AX double-positive cells (shaded). Cells with > 9 foci were counted as positive. At 
least 200 nuclei were scored per treatment in each experiment. Results from three independent 
experiments. Error bars, s.e.m. 
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Figure 3.28. RAD51 and γH2AX colocalization at CPT-damaged replication forks upon 
RECQ1 depletion and/or PARP1 inhibition. (a) Representative images of immunofluorescence 
in U-2 OS cells transfected with siLuc or siRECQ1, untreated or treated with 25 (not shown) or 100 
nM CPT for 1 hour, with 10 µM Olaparib or DMSO and stained for chromatin-bound γH2AX and 
RAD51 after 3 hrs release in fresh medium containing Olaparib or DMSO, detergent extraction and 
fixation. Nuclei were stained with Toto3 and merged fluorescence images are showed. (b) Results 
show the percentage of γH2AX positive cells and the RAD51/γH2AX double-positive cells 
(shaded). Cells with > 9 foci were counted as positive. At least 200 nuclei were scored per 
treatment in each experiment. Results from three independent experiments. Error bars, s.e.m.
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4  DISCUSSION 
	  
Replication fork regression is rapidly emerging as a pivotal mechanism of replication 
stress response. Preliminary studies performed in bacteria have underlined the importance 
of this process for the restart of damaged DNA replication forks more than 30 years ago 73. 
Conceptually, the mechanism of fork regression and restart has been suggested to aid the 
cells overcoming replication stress in at least three ways. First, pairing of the nascent 
strands allows error free bypass of template damage by repositioning the lesion in a double-
stranded DNA structure that will facilitate its repair. Second, the lesion is simply skipped 
and DNA synthesis primed ahead. Third, the backward migration of the branch point of a 
replication fork impedes the collision with breaks and/or roadblocks, providing the 
necessary room and time for the repair machinery to be recruited on and to fix the lesions. 
Despite these speculations, EM analysis of replication intermediates performed in S. 
cerevisiae have shown that regressed forks, along with aberrant structures such as gaps and 
partially replicated molecules, accumulate upon HU treatment only in a checkpoint-
deficient background. The authors interpreted the formation of regressed forks as the 
pathological destabilization of stalled replication forks in absence of a functional 
checkpoint. Under these conditions, the reversed forks collapsed and were unable to restart, 
leading to chromosome aberrations and cell death 26. Moreover, recent studies 
demonstrated that HU-induced fork reversal is counteracted by the Dna2 nuclease activity 
in S. pombe, which, under the checkpoint-mediated phosphorylation control, cleaves 
single-strand flaps that dissociate from the nascent strand to form a reversed fork 121. These 
notions lead to the idea that regressed forks merely represent pathological structures in 
yeast arising from destabilization of stalled forks. On the other hand, recent studies showed 
that Top1 inhibition induces replication fork slowing and reversal in a process that prevents 
double-strand break formation at clinically relevant CPT doses 117. This is the first evidence 
that fork reversal occurs also in mammalian cells and, more importantly, it represents a 
physiological controlled process that contribute to maintain genomic integrity upon fork 
blockage. A crucial cellular mediator required to accumulate/stabilize regressed forks upon 
Top1 poisoning is PARP1. PARP1 itself is a target for anticancer therapies, most 
conspicuously in BRCA-mutant breast and ovarian cancers 118. Moreover, PARP inhibition 
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leads to increased sensitivity to a broad range of chemotherapeutics, such as alkylating 
agents or different camptothecin derivatives, and combinatorial therapies are under clinical 
trials 288. PARP activation at CPT-damaged replication forks promotes the accumulation of 
regressed forks in a checkpoint- and recombination-independent manner 117. However, the 
mechanism by which PARP activity promotes fork reversal is still unknown, and the 
requirements for the restart of reversed forks have not been defined.  
The work reported in this thesis provides answers to all these questions. First, our results 
show that regressed forks can restart in vivo and identify a key role for human RECQ1 in 
promoting efficient replication fork restart after Top1 inhibition by virtue of its 
helicase/branch migration activities. Importantly, our results also show that this is a 
specific function of RECQ1 not shared by other helicases, such as BLM and WRN. 
Furthermore, our results provide new insight into the molecular role of PARP in fork 
reversal by showing that the poly(ADP-ribosyl)ation activity of PARP is important to 
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Figure 4.1. Schematic model of the combined roles of PARP1 and RECQ1 in response to 
Top1 inhibition. (a), (b) PARP poly(ADPribosyl)ation activity is not required to form reversed 
forks, but it promotes the accumulation of regressed forks by inhibiting RECQ1 fork restoration 
activity, thus preventing premature restart of the regressed forks. (c) Inhibition of PARP activity 
leads to replication run-off and increased DSBs formation upon Top1 inhibition, as RECQ1 can 
cause untimely restart of reversed fork. (d) PARP activity is no longer required in RECQ1-depleted 
cells were regressed forks accumulate because the cells lack the enzyme (RECQ1) necessary to 
promote fork restart. Homologous recombination (HR) might be required to promote fork restart in 
the absence of RECQ1 and PARP activity. 
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An intriguing aspect of these data is that PARP activity does not appear to be required to 
form reversed forks (Figure 4.1a), but rather to "accumulate" them, that is to 
maintain/protect them from a counteracting activity (RECQ1), which would otherwise 
restart reversed forks untimely, before Top1-DNA complex removal, leading to DSB 
formation (Figure 4.1c). Indeed, we show that, differently from control cells, PARP 
activity is dispensable to accumulate reversed forks and to avoid CPT-induced DSB in 
RECQ1 depleted cells (Figure 4.1d). We propose that PARP "signals" the presence of 
lesions on the template and inhibits locally RECQ1 thereby restraining the restart of 
reversed forks until Top1cc repair is complete. After the damage gets fixed, PARP1 is not 
longer activated and PARG-mediated PAR degradation might be responsible to set RECQ1 
free to reset a functional replication fork (Figure 4.1b).  
Which are the actors that might be required to promote fork regression rather than restart is 
still an open question, and a large number of helicases/translocases has been shown to 
catalyze this reaction in vitro. However, the particular structure of the stalled replication 
forks generated upon treatment with different types of genotoxic agents might dictate the 
differential requirement of motor enzymes to promote this reaction. Top1 inhibition by 
CPT derivatives was shown to trigger fork slowing due to the accumulation of positive 
supercoils ahead of the advancing replisome 115. In this context, the torsional force can 
potentially drive spontaneous fork regression without the need of any specific factor to 
actively promote this reaction, as previously suggested by in vitro studies 105. Moreover, 
little ssDNA is expected to form at these stalled structures since there should not be any 
polymerase-helicase uncoupling, ruling out an immediate checkpoint involvement as in the 
case of HU or UV treatment. Several evidences suggest indeed that CPT-induced fork 
slowing and reversal could result from local accumulation of torsional stress in vertebrates. 
First, Brdu Chip-chip analysis of synchronized, CPT-treated S. cerevisiae cells has been 
used to show that fork slowing and reversal are more frequent at chromosomal locations 
that are particularly susceptible to topological stress, such as highly transcribed or 
termination zones 117. Indeed, Top1 was shown to prevent the genomic instability arising 
from the interference between transcription and replication 289. Second, the checkpoint 
signals prevent the accumulation of reversed forks that arise as a consequence of torsional 
stress generated ahead of replication forks encountering transcribed genes in budding yeast, 
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by releasing their tethering to nuclear pores 108. The same group was able to show a 
checkpoint-independent accumulation of cruciform structures by genetic inactivation of 
Top1 and Top2 108. Collectively, these findings suggest that fork reversal can occur 
spontaneously as a thermodynamic favorable event to dissipate the torsional stress 
accumulating ahead of the advancing replisome following Top1 inhibition.  
In addition to CPT derivatives, oxidative or alkylating modifications of DNA were shown 
to trap Top1-DNA covalent complexes by perturbing the correct positioning of the two 
ends of the SSB, thus impeding the religation step 290, 291, 292. Intriguingly, co-IP 
experiments showed that RECQ1-PARP1 interaction increases not only after Top1 
inhibition, but also upon MMS and H2O2 treatment. Moreover MMC, an interstrand cross-
linking agent that blocks replication impeding fork unwinding, increases RECQ1-PARP1 
association as well. On the contrary, we were not able to observe an increased interaction 
between RECQ1 and PARP1 upon HU or aphidicolin treatment (data not shown). This 
result is unlikely to be due to a poor PARP1 activation since it has been already shown that 
PARP is activated in vitro and in vivo by HU-stalled forks to promote HR repair 256. The 
fact that the interaction between RECQ1 and PARP1 is conserved in the presence of 
different genotoxic agents suggests that these two factors play a conserved role in 
mediating fork reversal and restart upon treatment with all these drugs. However, the 
RECQ1-PARP1 pathway might be regulated by different factors or events such as protein-
protein interactions and post-translational modifications, depending on the particular 
structure of the stalled fork. For example, lysine acetylation is a mechanism that prevents 
PAR-protein binding by shielding the positive interacting surface, and thus introducing a 
further layer of regulation to PARP1-mediated signaling than the simple PARG-mediated 
PAR degradation 293. Recently, RECQ1 was shown to be acetylated at two lysines located 
on its WH domain following etoposide treatment 294; the WH domain is also crucial for 
RECQ1 interaction with PAR/PARP1 as demonstrated from this work.  An intriguing 
possibility is that RECQ1 acetylation prevents PAR binding, counteracting the inhibitory 
effect on its branch migration activity. Further experiments are needed to prove this 
hypothesis and/or to identify factors that modulate the activities of RECQ1 and PARP in 
fork reversal and restart. 
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Our results also provide new data on the biological processes in which PARP1 is 
involved to maintain the genome stability. Poly(ADP-ribose) is a flexible, short-life 
modification which not only acts as chromatin docking site for protein recruitment, but, 
due to its negatively charged nature, can modify the biochemical properties of proteins, 
such as their affinity for DNA and RNA or their ability to interact with other proteins 231. In 
our case, PAR formation is important to recruit and concentrate RECQ1 molecules on 
CPT-damaged replicative chromatin, and to keep them in an “inactive” state. Indeed, PAR 
inhibits RECQ1 oligomeric association with DNA, possibly preventing the interaction of 
the WH domain, with DNA or with other RECQ1 molecules. For this reason, it is possible 
that PAR inhibits the fork restoration activity of RECQ1 by preventing RECQ1 oligomer 
association with structured DNA, which has been previously proved to be critical for the 
branch migration activity of RECQ1 128, 135. Further investigation will be needed to validate 
this hypothesis. 
RecQ helicases are DNA unwinding enzymes essential for the maintenance of genome 
stability in many organisms 122. Why human cells should encode five RecQ homologs, 
while microorganisms like E. coli, S. cerevisiae, and S. pombe posses only one or two 
remains unexplained. Our previous studies identified important and distinct roles of 
RECQ1 and RECQ4 during DNA replication 202. These data, combined with previous 
observation that RECQ1 depletion leads to increased DNA damage and affects cellular 
proliferation 214, 218, suggest that RECQ1 plays a role distinct from the other human RecQ 
helicases in the stabilization and/or repair of replication forks. Our discovery that RECQ1 
is required for replication fork restoration after Top1 poisoning provides the first indication 
of a specific cellular function for RECQ1. U-2 OS cells lacking BLM or WRN do not show 
similar defects in replication fork restoration upon Top1 inhibition, suggesting that RECQ1 
is the only RecQ helicase responsible to promote replication fork restart upon CPT-induced 
fork reversal. In agreement with this conclusion, chromatography-fractionated nuclear 
extract from RECQ1-depleted HEK 293T cells showed impaired HJ branch migration 
activity in vitro; this effect was not recapitulated by the lack of other RecQ helicases, such 
as WRN and BLM, or other HR enzymes such as RAD54, thus indicating RECQ1 as the 
major branch migrating protein in human cells 223. Moreover, RECQ1 shows a striking 
preference for fork restoration versus regression while other helicases/translocases have 
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been shown to indiscriminately perform both reactions 30, 91, 153, 154. However, we cannot 
rule out the possibility as yet that other motor proteins are involved in different steps of the 
same process.  
Important avenues for future studies will be to determine whether reversed forks are 
detected in response to genotoxic agents other than Top1 inhibitors and whether other 
helicases are implicated in replication fork reversal and/or restart depending on the 
particular type of DNA damage.  In this regard, WRN- and BLM-deficient cells display 
increased sensitivity to selected genotoxic agents 295, while RECQ1-deficient cells are 
markedly sensitive to CPT and etoposide supporting the notion that these three RecQ 
helicases play distinct roles in replication stress response. The fact that RECQ1-depleted 
cells show an increased sensitivity to etoposide opens the interesting possibility that a 
similar mechanism of fork reversal and restart might take place upon treatment with Top2 
poisons. EM analysis of replication intermediates after treatment with different classes of 
chemotherapeutic drugs will provide early clues to the most interesting combinations of 
drugs and RecQ helicases to pursue in future studies.  
The data reported in this thesis also provide new mechanistic insight to predict the 
efficiency of combinatorial anticancer therapies with PARP and Top1 inhibitors. These 
combinations are currently in clinical trials 119. The fact that PARP inhibition is dominant 
over RECQ1 depletion on Top1 sensitivity is somehow surprising, considering that PARP 
activity is irrelevant in preventing replisome run-off at Top1cc and DSB formation in 
absence of RECQ1. A possible explanation is that PARP activity regulates additional 
biological processes associated with Top1 poisoning in addition to fork reversal and restart, 
such as Top1-DNA covalent complex removal 296, chromatin remodeling 240, 241 or even 
proper establishment of the HRR 256. Indeed a genome-wide siRNA screen on HeLa cells 
has identified PARP1 as one of the genes, along with key recombination factors, displaying 
the strongest sensitive phenotype upon camptothecin exposure 286. Several groups have 
previously shown that in chicken DT40 cells PARP1 activity is essential to counteract the 
toxic engagement of NHEJ in repairing DSBs arising from replication failure, likely by 
decreasing the strong affinity for DNA of Ku heterodimer through its poly(ADP-
ribosyl)ation,  and thus  channelling the repair to the HR pathway 259, 260, 261. Indeed 
increasing evidences suggest a conserved, inhibitory/competitive role of Ku for HRR 297, 
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298; in the absence of PARP activity unrestricted binding of Ku70/86 heterodimer to DSBs 
arising from replication fork breakage might prevent access to the end resection machinery 
required to generate a proper 5’-ssDNA for RAD51 loading, and/or trigger aberrant fusion 
of breaks located in different chromosomes. Given the particular structure of a regressed 
fork, the double-stranded end (DSE) of its extruded arm might be recognized by different 
DNA repair factors as a broken chromosome. Hence, PARP1 activity would be crucial to 
avoid aberrant NHEJ repair and allow the proper HR-mediated processing of reversed 
forks. In agreement with this conclusion, we observed a significant decrease of RAD51 
foci formation upon Top1 and PARP inhibition, even in the absence of RECQ1. In this 
regard, it is also important to mention that Ku heterodimer was identified by mass 
spectrometry as one of the most abundant factors present the RECQ1 complex. Defining 
the role of the Ku heterodimer and HRR in the process of PARP1/RECQ1-mediated fork 
regression and restart is an essential topic for future investigations. 
Our results also suggest that RECQ1 itself might represent a new target to be exploited 
in conjunction with Top1 for chemotherapy. Inducing fork reversal (Top1 poisons) and 
inhibiting reversed fork reactivation (RECQ1 depletion) is expected to synergize, 
explaining the observed CPT-sensitivity of RECQ1-depleted cells. RECQ1 is 
overexpressed in several kinds of tumors 214 and its depletion has been show to trigger 
mitotic catastrophe specifically in cancer cells 219. One explanation might be the inability of 
RECQ1 depleted cells to restart reversed forks produced by chemotherapeutics or simply 
by oncogene-induced transcriptional perturbation of DNA replication and complete the 
DNA synthesis, thus leading to this form of mitotic apoptosis.  
In last analysis, we showed that RECQ1 depletion leads to a dramatic increase in RAD51 
foci formation upon Top1 inhibition, suggesting that the RECQ1-mediated mechanism of 
fork restart is a way to process reversed replication forks in a safe, non-recombinatorial 
way. Increasing evidences suggest that HRR can be considered as a “double-edged sword” 
and, even if crucial for completing DNA synthesis and guarantying cell survival upon 
replication stress, it represents an error-prone process that leads to complex genomic 
rearrangements, particularly due to the high content of repetitive sequences in mammalian 
genome 299, 300, 301, 302. This aspect is particularly relevant for highly proliferating cancer 
cells, which depend on this pathway to deal with their constitutive replication stress at the 
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expense of genomic stability, thus acquiring mutations that further fuel their oncogenic 
potential. Therefore, cells have evolved specific mechanisms to overcome replication 
damage without the need of the HR pathway. Failure of such processes channels the repair 
of damaged replication forks into a potentially harmful homology-directed repair. In such a 
scenario, RECQ1 depletion triggers to an unscheduled accumulation of regressed 
replication forks, which are subsequently taken over and processed in a recombinogenic 
way, thus switching the nature of these structures from physiological to potentially 
pathological. Our preliminary findings confirm that regressed forks, if not properly 
restarted, represent indeed a recombinogenic substrate, as previously suggested for yeast 26. 
Moreover seminal studies performed in prokaryotic cells have shown an extensive 
involvement of HR factors in the fork reversal/resetting process 75. Due to the particular 
structure of a regressed fork which arbors a four way junction and a double-stranded end, it 
remains to verify if HRR can directly acts on these structures, or if the junction need to be 
processed by other factors, such as by selective-substrate endonucleases like Mus81-Eme1 
or Slx1-SLx4, in order to recreate an one-side DSB. Our experimental findings such as 
accumulation of regressed forks and RAD51 foci formation in the absence of DSBs upon 
CPT treatment of RECQ1-depleted cells, favor for the first hypothesis and suggest the 
loading of RAD51 on the extruded arm of a regressed fork, probably upon proper 5’-3’ 
resection, without the need of a DSB. Consistently, RAD51 was shown to be loaded on 
replication forks stalled by interstrand cross-linking agents, before the DSB formation 
mediated by FANCD2 and specific endonucleases 303. All together these preliminary results 
open up new avenues of research on the HR-mediated mechanism of regressed fork 
processing in mammalian cells. More importantly, unscheduled accumulation of regressed 
forks upon RECQ1 depletion or inhibition might result in synthetic lethality in a HR-
deficient background, thus providing a novel way to target and increase the efficacy of 
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